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I N T R O D U C T I O N
1.1 prostate cancer
The prostate gland is part of the male reproductive system and can be ana-
tomically divided into three main zones: the transition and central zone, which
together comprise the central gland, and the peripheral zone. The prostate
can undergo vast changes during a man’s lifetime. Along with prostatitis and
benign prostatic hyperplasia, prostate cancer is a common pathological condi-
tion. Prostate cancer (PCa) affects more than 40% of men over the age of 60 [1].
Worldwide, it is the second most frequently diagnosed cancer in males next to
lung cancer, and the most common non-cutaneous malignancy among men in the
Western world [2, 3]. Incidence rates of PCa vary geographically but have seen
an overall increase whereas mortality rates have declined in most countries [4].
Considering that the global population aged 60 or more is expected to nearly
double by 2050 [5], the management of age related diseases such as PCa, while
ensuring a good quality of life, presents a health challenge worldwide.
In clinical practice, increased prostate-specific antigen (PSA) levels are
used as biomarkers for PCa. However, PSA screening is controversial because
although there is evidence that it leads to a reduction in PCa-specific mortality,
it does not seem to have an effect on overall mortality rates [6]. Additionally,
PSA is not PCa specific, as a number of benign conditions can also result
in a PSA rise. The ongoing debate is focused on how to prevent overdia-
gnosis and overtreatment of clinically insignificant cases. The main treatment
options are radiotherapy (RT) and the surgical removal of the prostate gland
(prostatectomy). The field of RT has seen great technological advances in the
past decades, with improvements in patient position verification and delivery
techniques allowing for more conformal dose distributions. Similarly, the in-
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troduction of robot-assisted surgery allows surgeons to perform more precise
dissections potentially leading to better preservation of functional structures
[7]. Improvements in diagnosis and treatment options have led the 5-year age-
adjusted survival rates to increase from 49% in 1970 to 89% in 2015 [8].
1.2 imaging for the staging of primary
prostate cancer
1.2.1 Local staging
In the diagnosis of PCa, multi-parametric MRI (mp-MRI) refers to an MRI
protocol typically consisting of high-resolution T2-weighted (T2w) anatomical
scans, as well as at least two functional sequences [9]. When performed before
biopsy, it is a sensitive tool to detect clinically relevant tumour and to localise
sites for targeted biopsies [10]. This is the technique of choice for local tumour
staging (T “staging”), as it allows the identification of extracapsular extension
and seminal vesicle invasion.
The most relevant anatomical sequence for detection of primary PCa is a
T2w scan. This sequence offers a good depiction of the gland anatomy, where
a tumour region can be identified as hypointense due to its shorter T2 decay.
In PCa, the two main tissue properties probed with functional MRI are
diffusion and perfusion. Diffusion-weighted imaging (DWI) probes the random
translational motion of water molecules. As tumour tissue is characterised by
increased cellular density, these densely packed regions restrict the extracellu-
lar movement of water molecules, resulting in hyperintense regions in the DWI
sequence. An apparent diffusion coefficient (ADC) map can be derived from
DWI images acquired at different gradient strengths. The ADC map provides
a quantitative measure of restricted diffusion for each voxel and is usually low
in tumour regions. Dynamic contrast-enhanced (DCE) MRI is used to quantify
tissue perfusion by dynamically monitoring the distribution of injected contrast
agent in the region of interest. The high energetic demand of growing tumour
cells is accompanied by the formation of a new vascular bed which is often
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disorganised, inefficient and leaky. These abnormal perfusion characteristics
can be imaged and distinguished from those of healthy tissue, and a quantific-
ation of vessel permeability can be obtained by using tracer kinetic modelling.
In prostate tissue, the Tofts model is commonly used, yielding values for the
volume transfer constant of contrast agent molecules through the capillary en-
dothelium (Ktrans), the volume of the extravascular-extracellular space (ve) and
the rate constant between the extravascular-extracellular space and the plasma
(kep). Tumour tissue is associated with elevated Ktrans and kep values.
1.2.2 Nodal and metastatic staging
The detection of nodal spread (“N” staging) can be performed with abdominal
CT, anatomical MRI or positron emission tomography (PET). Both CT and MRI
methods indirectly assess nodal invasion by allowing the measurement of nodal
diameter and morphology. However, the sensitivity of these methods is only
around 40% on the basis of a 10 mm threshold for nodal involvement [11]. 68Ga-
or 18F-labelled prostate-specific membrane antigen ligands (PSMA) PET is
increasingly being used, since preliminary evaluations have shown promising
sensitivity for the detection of lymph node involvement [12–14]. For the assess-
ment of metastatic spread (“M” staging), which in PCa usually takes the form
of bone metastasis, bone scintigraphy (also known as bone scan) has been the
most widely used method [15], albeit with an increasing popularity of PSMA
scans [16]. The tumour, nodal and metastatic staging results form together the
TNM staging, a clinical parameter used to define tumour spread.
1.2.3 Prostate cancer risk groups
The Gleason grading system is used to evaluate the histopathology of the biopsy
specimen by describing the glandular pattern and the degree of differentiation.
In combination with the TNM staging and the measured PSA values, it is
used to assess the tumour risk and to ground treatment decisions. Prostate
cancer can thus be categorised in three different risk groups. According to the
European Association of Urology (EAU) guidelines [15], low-risk PCa is defined
by a tumour with a clinical T-stage of cT1-2a, with a Gleason grade <7, and
PSA values <10 ng/ml. When the PSA values are between 10-20 ng/ml, or the
Gleason grade = 7, or the clinical T-stage is cT2b, the tumour is categorised as
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intermediate-risk PCa. If the PSA values are >20 ng/ml, or the Gleason grade
is >7, or the tumour extends to both lobes having thus a clinical T-stage of
cT2c, the tumour is defined as high-risk PCa. While the previous descriptions
relate to localised prostate cancer, high-risk tumours can also extend beyond
the prostate in which case they are referred to as locally advanced. These
are characterised as either a clinical T-stage > cT3 or positive regional lymph
nodes (cN+) with any PSA and Gleason grade values.
1.3 radiotherapy as a treatment option for
primary prostate cancer
Alongside radical prostatectomy, RT is one of the main treatment options for
primary PCa and can be administered in two main forms: interstitially in the
form of brachytherapy or as external-beam radiotherapy (EBRT). Brachytherapy
can be delivered by permanently implanting radioactive seeds (low dose-rate
brachytherapy, LDR) or by using needles and an afterloading device to transport
a radioactive source close to the target for a pre-determined period of time (high
dose-rate brachytherapy, HDR). EBRT treatments deliver the dose by using a
combination of radiation beams generated by a linear accelerator and adapted
to maximise target coverage.
Disease extent, tumour differentiation grade and the patient’s preferences
influence the choice for a specific treatment strategy. Tumours of any differ-
entiation grade that are locally confined without extracapsular extension can
be treated with either radiotherapy or prostatectomy. According to the EAU
guidelines, brachytherapy in the form of LDR should be restricted to prostate
volumes of less than 50 cm3 and is an appropriate treatment option for patients
with locally confined and moderate or well-differentiated tumours, while HDR
can be offered to men with poorly differentiated tumours and/or with higher
tumour volumes [15]. EBRT (at times combined with HDR brachytherapy) is
the treatment of choice for those with suspected extraprostatic extension. In pa-
tients with moderate and poorly differentiated tumours, EBRT can be combined
with adjuvant or neo-adjuvant hormonal therapy.
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During EBRT treatments, the dose is delivered in several fractions. Before
each fraction, images are acquired for patient position verification. Visualisation
of the prostate gland in the daily acquired cone-beam CT (CBCT) or electronic
portal imaging device (EPID) images is challenging due to the poor soft-tissue
contrast. Therefore, typically three to four gold fiducial markers are implanted
in the prostate gland prior to treatment to allow daily verification of the patient
position. These are visible in the planning CT and in the daily acquired CBCT
or EPID images (obtained via devices integrated in the linear accelerator), and
are used as a prostate surrogate. A transition towards an MR-only treatment
planning workflow is currently under investigation. In the first stages, MRI is
employed exclusively for treatment planning while the conventional Linac ma-
chines with CBCT position verification are used to deliver the treatment. In
this setting, fiducial markers are still used for patient position verification, and
one precondition to implement an MR-only treatment planning workflow is the
ability to detect them on MRI. However, due to their paramagnetic properties
they present as local signal voids on most MR images. Sequence specific para-
meters influence the appearance of the marker voids, increasing the complexity
of reproducible and accurate manual marker localisation on MRI. While the
implementation of MR-Linac systems will eventually render obsolete the use
of fiducial markers for patient position verification, these systems have only
recently been clinically implemented and are not widely available. Brachyther-
apy seeds are usually encapsulated in titanium, resulting in artefacts similar
to those of the markers on the MR images. Since the markers and seeds are
permanently implanted, these effects must be taken into consideration when
assessing MRI scans of patients after primary RT treatment.
1.3.1 Treatment outcome prediction
Clinical nomograms, such as the Kattan nomogram [17], use the patient’s clin-
ical characteristics to provide an indication of the risk of biochemical recurrence.
However, such clinical parameters fail to explain some of the variability seen
in patient outcome. Improved stratification can potentially be obtained by in-
cluding information from pre-treatment imaging.
MRI scans are commonly acquired for the purpose of tumour staging and
treatment planning, and evidence is emerging that factors such as tumour ag-
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gressiveness are associated with specific textural features from MR imaging
[18, 19]. MRI-derived features could potentially provide insight into the recur-
rence risk. Visually scored, MRI-based, semantic attributes of PCa, such as
seminal vesicle invasion or extracapsular extension, are predictors for 5-year
biochemical recurrence free survival. These predictors improve staging, thereby
augmenting the performance of predictive models which combine them together
with clinical nomograms [20]. In heterogeneous cohorts, tumour-extracted ima-
ging features from T2w MRI were associated with recurrent disease after RT
[21]. This information might be used to determine in which patients conven-
tional treatment is likely to succeed and those where intensification would be
beneficial. Specifically for high-risk patients, who bear the highest recurrence
rates [22], early identification of increased recurrence risk can potentially im-
pact clinical management and subsequent follow-up.
1.4 recurrent prostate cancer after
radiotherapy: incidence and treatment
options
After RT, PSA values gradually decrease until they reach their lowest level
(nadir). If after the initial treatment the PSA values rise above a predefined
level there is a concern of a recurrent tumour, and this increase is defined as
‘biochemical recurrence’. One of the most widely used definitions for biochemical
recurrence is a PSA rise of 2 ng/ml above the nadir (Phoenix definition) [23].
A recent study analysing a series of 2694 patients treated with doses equal to
or greater than 75.6 Gy reported 8-year biochemical recurrence risks of 10%,
23%, and 43% in low-, intermediate-, and high-risk PCa patients, respectively
[24]. Thus, for a proportion of patients the primary RT will fail to eradicate the
tumour.
For patients with recurrent disease after RT, the standard management is
currently androgen deprivation therapy (ADT), adapted according to disease
extent and progression rate. ADT is given with the intent of delaying disease
progression, but it will not prevent metastatic spread and eventual death. It
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is further associated with severe side-effects that can strongly impact a pa-
tient’s lifestyle [25]. While most patients with recurrent disease have already
developed metastases, Hruby et al. [26] and Bolla et al. [27] found that 17-20%
of the patients will harbour locally recurrent disease only. For these, curative –
commonly denominated “salvage” - treatment options can be offered, including
radical prostatectomy, brachytherapy, cryotherapy, or high-intensity focused ul-
trasound (HIFU). The oncologic outcomes seem to be comparable between the
available whole-gland salvage treatment options [28]. However, conventional
whole-gland treatments can result in substantial morbidities, such as incontin-
ence, rectal injury and bladder neck stricture [29, 30], and should only be offered
to highly selected patients [31]. The toxicity associated with whole-gland ap-
proaches has made physicians reluctant to refer patients for salvage treatments.
Reports indicate that only 2% of radiation failures are currently managed with
local salvage treatments. The rest of the patients are either immediately treated
with ADT, or managed with observation and, if deemed necessary, started on
ADT [32].
To overcome the toxicity related to whole-gland strategies, while maintain-
ing local control, focal treatments targeting the index lesion while sparing the
surrounding uncompromised tissue can be offered to selected patients. The
commonly offered whole-gland salvage approaches can then be designed with
focal intent and with different ablation extents, ranging from ultrafocal, to hemi
or quadrant-wise. Functional and oncological outcomes differ per modality and
ablation extent, and no randomised trials have yet been performed to ascertain
which modality and ablation scheme is optimal. Overall, the 5-year biochemical
failure-free survival is between 46.5-54.5% [33]. Moreover, Duijzentkunst et al.
[33] suggested that focal salvage treatments could decrease severe genitour-
inary (GU) and gastrointestinal (GI) toxicities, potentially preserving erectile
function.
1.5 imaging in recurrent prostate cancer
Radiographic detection of recurrent PCa in the context of biochemical recur-
rence is essential in evaluating disease spread, as well as to set expectations
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and determine an appropriate treatment for the patient. The most accurate
PET tracer for the detection of tumours and metastatic spread is currently
68Ga PSMA-PET [13], with reported detection rates of 48 - 63.5% for locally
recurrent PCa cancer after RT [26, 34]. On the other hand, mp-MRI, using
both anatomical and functional sequences, is increasingly used to stage locally
recurrent disease [35–37], and it has been reported to obtain good sensitivity
in detecting radio-recurrent PCa [38–41]. The previous RT treatment has likely
impact not only on the structure but also on the physiology of the prostatic tis-
sue. So far, a quantitative characterisation of mp-MRI in the recurrent setting
after RT has not been established and it remains to be defined which sequences
are preferred for the detection of recurrent PCa. Currently, the sequences per-
formed for the detection of recurrent disease are typically similar to those used
in the primary setting.
Distinguishing between local recurrence and metastases is critical in de-
termining whether treatment with local salvage therapy is sufficient, or if sys-
temic treatment should be provided to control disease progression. To this
end mp-MRI findings are used in combination with those from PET to reach a
diagnosis.
1.5.1 Image assessment
68Ga PSMA-PET is increasingly being used to assess metastatic spread, where-
as mp-MRI can be used to evaluate intraprostatic disease. In the setting of
primary PCa, the PI-RADS v2 consensus guidelines [42] were established to
inform radiologists on how to interpret and rate the different mp-MRI sequences
for the likelihood of tumour presence. However, these guidelines are not ap-
plicable in the recurrent setting.
After RT, the interpretation of mp-MRI is complicated due to the presence
of RT-induced benign confounders [36, 37, 43]. The prostate tissue presents
with an overall diffuse signal intensity reduction in the T2w sequence, which
complicates tumour detection [37]. Furthermore, DCE-derived maps can present
with a benign increased enhancement in the peri-urethral tissues [44]. Conflict-
ing results have been published regarding the importance of the different MRI
sequences in the detection of recurrent PCa. The use of 1.5T MR spectroscopy
[45] as well as DWI- and DCE-MRI [39, 40] in addition to T2w were found to
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improve local recurrence detection. On the other hand, Donati et al. [46] and
Luzurier et al. [47] found no additional benefit of DCE when added to T2w
and DWI. To date, there are no guidelines on how to score or delineate recur-
rent tumours on mp-MRI, and the relevance of each abovementioned imaging
sequences has yet to be determined for recurrent PCa.
Little is known regarding the effect of RT on the mp-MRI characteristics of
benign tissue. An accurate description of mp-MRI characteristics of benign tis-
sue after RT is necessary to establish a baseline reference against which suspi-
cious findings can be compared. This would facilitate the design of radiological
reporting guidelines and result in easier image interpretation. Currently, and
in the absence of further guidance, PI-RADS v2 is often still used as a starting
point for image assessment.
1.6 focal salvage treatments: how to
localise the area to treat?
Understandably, delineation of the target volume is of great importance in RT.
Nevertheless, it remains one of the weakest links in the treatment chain [48,
49]. While whole-gland treatments are standard for primary PCa, the number of
studies reporting on focal approaches is increasing. Yet, the lack of contouring
guidelines results in large reported inter-observer variability when delineating
primary PCa on mp-MRI [49, 50]. It may be inferred that accurate delineations
are just as important in the focal treatment of recurrent disease, potentially in-
fluencing local tumour control. Thus, methods to decrease variability in defining
the region to treat are warranted.
Even though 68Ga PSMA-PET offers high sensitivity in detecting recur-
rent PCa, the high-resolution anatomical and functional possibilities offered by
MRI, together with a good accuracy in detecting recurrent disease extension
[51], make this an attractive technique to use for the design of focal salvage
treatments [52]. In studies reporting on focal salvage treatments, the target is
commonly defined with the use of MRI, often combined with biopsy results [53,
54]. Given that there is yet to be a consensus on which imaging sequences
focal salvage treatments: how to
localise the area to treat?
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should be used to identify recurrent tumour, as well as the varying definitions
of focal treatment (i.e. ultrafocal, hemi, etc.), the target volumes reported in
literature are highly variable and not directly comparable.
To validate imaging findings the gold-standard is histopathology validation.
Biopsies are prone to sampling errors and fail to capture the spatial heterogene-
ity of the underlying tissue. Thus, prostatectomy samples represent the most
complete histopathology reference. However, salvage prostatectomy after RT is
only rarely performed due to high treatment-related toxicity rates. Only a few
whole-mount histopathology validated studies exist on the MRI properties of
recurrent tumour after radiotherapy [45, 55, 56]. From the available studies with
salvage prostatectomy samples, evidence is emerging that recurrent tumour is
multifocal [57] but with intraprostatic failures occurring predominantly at the lo-
cation of the primary index lesion [55]. There are no studies that have registered
the histopathology to MRI, which would enable a more accurate characterisation
of tumour and healthy tissue.
1.7 aims and outline of this thesis
Despite the technical advancements of recent decades, around 25% of all PCa
patients treated with RT will experience a biochemical recurrence and a sig-
nificant minority will have an exclusively local failure. The general aim of this
thesis is to improve the detection and localisation of locally recurrent PCa after
RT using mp-MRI. The different sections of this thesis are focused on improving
the stratification of recurrence risk, detection, and definition of the region to
treat with focal salvage therapies. More specifically, the research questions to
be addressed in the following chapters are:
Part 1 - Magnetic resonance imaging in the treatment and outcome prediction
of primary prostate cancer
• Can pre-treatment MRI features be used to improve patient stratification
for the risk of experiencing biochemical recurrence?
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• Is it possible to automatically detect gold fiducial markers on MRI?
Part 2 - Magnetic resonance imaging for the diagnosis and localisation of
recurrent prostate cancer
• What are the quantitative mp-MRI characteristics of benign tissue after
radiotherapy?
• What are the quantitative mp-MRI characteristics of recurrent tumours
after radiotherapy?
• Can mp-MRI be used to automatically define a region to treat with focal
salvage treatments?
The studies described in the first part of this thesis are focused on the role
of mp-MRI in the treatment of primary PCa. Chapter 2 evaluates the potential
of whole-gland T2w MR imaging features for 5-year biochemical recurrence
risk prediction in high-risk patients treated with RT for local primary PCa. Re-
current disease is a significant problem for patients treated with primary RT
for PCa. By identifying patients with high risk of recurrence prior to primary
RT, treatment intensification could be offered, for instance, by providing ad-
juvant ADT or a dose boost to the index tumour lesion. Fiducial markers are
implanted as part of the EBRT treatment for primary PCa and will therefore be
present when imaging patients with a suspected recurrence after RT. Chapter 3
describes how imaging features extracted from a combination of MRI sequences
can be used with a machine learning classifier to automatically detect fiducial
markers on MRI.
The second part of this thesis addresses the use of mp-MRI in the setting of
recurrent disease after RT. The detection of recurrent tumours at an early stage,
while disease is still confined to the gland, will potentially increase the success
rate of salvage treatments. In order to allow early detection, we must improve
the current diagnostic work-up for patients with suspected recurrence. After RT,
MRI interpretation is complicated by benign RT-induced imaging confounders.
To facilitate recurrent disease detection and distinction from benign changes,
in Chapter 4 a case-control study is used to establish a baseline reference by
characterising benign tissue and comparing it to recurrent disease using mp-
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MRI. By registering whole-mount slices of salvage prostatectomy specimens to
the mp-MRI acquired prior to the surgery, the pattern of recurrence after RT
as well as tumour imaging characteristics are presented in Chapter 5. Further-
more, manual MRI-based tumour delineations are compared to histopathology
findings. Chapter 6 describes how uncertainties in target volume delineation
can be overcome by incorporating all mp-MRI sequences to obtain voxel-wise
tumour probabilities that can be used to determine regions to target with focal
salvage treatments. Finally, the impact of the findings reported in this thesis
will be discussed in Chapter 7.
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abstract
Background and purpose: High-risk prostate cancer patients are frequently
treated with external-beam radiotherapy (EBRT). Of all patients receiving EBRT,
15-35% will experience biochemical recurrence (BCR) within five years. Mag-
netic resonance imaging (MRI) is commonly acquired as part of the diagnostic
procedure and imaging-derived features have shown promise in tumour charac-
terisation and biochemical recurrence prediction. We investigated the value of
imaging features extracted from pre-treatment T2w anatomical MRI to predict
five year biochemical recurrence in high-risk patients treated with EBRT.
Materials and methods: In a cohort of 120 high-risk patients, imaging features
were extracted from the whole-prostate and a margin surrounding it. Intensity,
shape and textural features were extracted from the original and filtered T2w-
MRI scans. The minimum-redundancy maximum-relevance algorithm was used
for feature selection. Random forest and logistic regression classifiers were
used in our experiments. The performance of a logistic regression model using
the patient’s clinical features was also investigated. To assess the prediction
accuracy we used stratified 10-fold cross validation and receiver operating char-
acteristic analysis, quantified by the area under the curve (AUC).
Results: A logistic regression model built using whole-prostate imaging fea-
tures obtained an AUC of 0.63 in the prediction of BCR, outperforming a model
solely based on clinical variables (AUC = 0.51). Combining imaging and clin-
ical features did not outperform the accuracy of imaging alone.
Conclusions: These results illustrate the potential of imaging features alone to
distinguish patients with an increased risk of recurrence, even in a clinically
homogeneous cohort.
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2.1 introduction
High-risk primary prostate cancer (PCa) patients are commonly treated with
radiotherapy (RT). According to the Phoenix definition, biochemical recurrence
(BCR) after RT occurs within five years in 15 - 35% of all cases [58–60]. Aiming
at better patient stratification, clinical nomograms, such as the Kattan nom-
ogram [17], have been developed to predict biochemical recurrence after RT.
These incorporate factors such as the PSA level and biopsy Gleason score,
known to be good predictors of biochemical recurrence, but are often limited
by the accuracy of the measured variables. The prognosis of high-risk PCa
patients is heterogeneous, however the available clinical nomograms are not
tailored to distinguish patients within a single risk group.
Magnetic resonance imaging (MRI) is well established for PCa diagnosis
and staging. T2-weighted (T2w) anatomical scans are used to assess the extent
of the tumour. Visually scored semantic attributes of PCa visible on T2w-MRI,
such as seminal vesicle invasion or extracapsular extension, are predictors for
five year biochemical recurrence free survival. By improving staging, these
predictors augment the performance of predictive models which combine them
together with clinical nomograms [20].
Radiomics has emerged as a field in which a high number of quantitative
imaging features are extracted from a region of interest (ROI) to quantitatively
describe its phenotype. Texture analysis based on the grey level co-occurrence
matrix (GLCM) [61], using second order statistics to characterise the spatial
dependence of grey-levels in an image, has been applied extensively to evaluate
both the location and aggressiveness of PCa [18, 19] based on T2w-MRI. By
assessing tissue micro-architecture and tumour aggressiveness, being the latest
by definition related with BCR, this modality could provide insight on recurrence
risk prediction.
Local recurrence after RT is reported to occur predominantly at the site of
the index lesion [55], and imaging features from the primary tumour were found
to strongly associate with the probability of BCR following RT [21, 62]. However,
these studies have relatively small and inhomogeneous patient cohorts, with the
study by Gnep et al. [21] having a median follow-up time of only four years. An
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early identification of increased recurrence risk can potentially impact clinical
management and subsequent follow-up, particularly for high-risk disease as it
is related with higher recurrence rates [22].
For many years, the standard for RT purposes was not multi-parametric
MRI (mp-MRI) but anatomical imaging with the goal of prostate gland delin-
eation. Thus, cohorts with longer follow-up are often restricted to T2w-MRI
and the uncertainty in tumour localisation is high. Tumour delineations on mp-
MRI are prone to inter-observer variations up to 2.3mm with smaller satellite
lesions being often missed [49]. No guidelines are yet available for this task.
Prostate delineations are also prone to inter-observer variability but radiolo-
gical guidance on how to delineate in T2w-MRI is available [63]. Evaluation of
whole-prostate imaging features avoids delineation uncertainty, is not restric-
ted to the visible tumour area and might therefore be sensitive to both micro-
and macroscopical features predictive of recurrence.
We here aimed to investigate the potential of whole-prostate imaging fea-
tures for five year BCR prediction after RT of local PCa, in a clinically homo-
geneous cohort of high-risk biopsy-proven PCa patients. We further analysed
the predictive value of features in the margin surrounding the prostate, as the
presence of extracapsular extension and seminal vesicle invasion is related to
the risk of relapse. The performance of models using imaging features was
compared to one using solely clinical features.
2.2 materials and methods
2.2.1 Dataset
In a single centre, patients with high-risk PCa were selected retrospectively
from a consecutive cohort treated with external-beam radiotherapy (EBRT)
between 2007 and 2011. Risk classification was performed according to the
D’Amico definition [64]. Further inclusion criteria involved having received hor-
monal therapy (HT), a dose of 78Gy in 39 fractions and no other pelvic comor-
18 biochemical recurrence prediction after radiotherapy
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bidities before the treatment. Biochemical recurrence was diagnosed according
to the Phoenix criteria [65] and all patients had five years of follow-up. A total
of 120 patients satisfied the inclusion criteria.
Pre-treatment clinical predictors of biochemical recurrence after EBRT
were chosen according to the input parameters of the Kattan nomogram [17].
2.2.2 MRI protocol
T2w anatomical MRI scans were acquired as part of the RT treatment planning
procedure. Axial T2w turbo-spin echo (TSE) and T2w 3D VISTA (for nine pa-
tients) sequences were acquired on a 3T Philips Achieva MRI scanner (Philips
Healthcare, Best, the Netherlands). For the TSE sequence the repetition times
(TR) were longer than 3800 ms, the echo times (TE) between 120 –150 ms and
the scans had an in-plane pixel pitch of 0.27 – 0.49 mm and slice thickness of
2.3 – 3.3 mm. For the VISTA sequence the TR = 2034 ms and TE = 120 ms,
with isotropic voxels of 0.8 mm width. Functional sequences were not part of
the RT clinical workup.
2.2.3 ROI segmentation
Prostate delineations were performed for all patients with an atlas-based ap-
proach using a research software version of ADMIRE 1.13.5 (Elekta AB, Stock-
holm, Sweden), with visual verification by the researcher (four years of experi-
ence in prostate delineation) and manual correction whenever necessary.
Based on the prostate delineation intra-observer variability reported by
Nyholm et al. [66], prostate ROIs were created by expanding the delineation
by 2mm to compensate for possible delineation uncertainties and to ensure
whole-prostate coverage. The margin ROIs were defined as the region between
an expansion and shrinkage of the prostate delineation by 2mm.
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2.2.4 Image feature extraction
The pyradiomics 1.2.0 toolbox [67] was used for region-wise 3D feature extrac-
tion. For a consistent calculation of 3D features, all images were resampled to
an isotropic grid of 2× 2× 2 mm voxels using BSplines to avoid extreme image
oversampling in the slice direction. Images were then normalised as described
in Appendix A. The normalised images, as well as images obtained by further
filtering with a Laplacian of Gaussian (LoG) with σ = 1, 3, and 5 mm, were
used as input for feature extraction. The extracted features were categorised in
shape, intensity and texture. From the LoG filtered images only intensity and
texture features were extracted.
Image discretization was performed by using a fixed bin width = 5. Ro-
tational invariant textural features derived from the grey-level co-occurrence
(GLCM) and run length (GLRLM) matrices were computed by averaging the
values obtained over 13 angles (0, 45, 90 and 135◦symmetrical angles in-plane
and out-of-plane) using a displacement vector of one voxel. These features
quantify regional heterogeneity.
A total of 254 region-level features were obtained per patient (Table 2.1
and Appendix B), all scaled as described in Appendix A.
2.2.5 Models and validation
Independent models were created using either clinical or imaging features. Sep-
arate imaging models were generated for each ROI. The clinical model was
developed using PSA, Gleason and clinical stage variables.
All models were independently validated using stratified 10-fold cross-val-
idation (CV), ensuring the folds preserve the percentage of samples for each
class. Receiver operating curve (ROC) analysis with the use of the area under
the curve (AUC) values per fold was applied to assess the prediction accuracy
for the different ROIs.
Clinical and imaging models were created based on different features, po-
tentially offering complementary information about the pattern to be classified.
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Combining the results of the two to generate a consensus decision may improve
efficiency and accuracy, as the sets of patterns misclassified by the different
models would not necessarily overlap [68]. To evaluate this hypothesis, the pos-
terior probabilities obtained for each patient for imaging and clinical models
were averaged in one joint probability, and the performance of the combined
models was assessed.
2.2.6 Feature ranking and selection
Due to the high dimensionality of the feature set, feature selection was im-
plemented to address the curse of dimensionality [69]. Within the stratified
10-fold CV scheme we aimed at identifying a model hyperparameter - the num-
ber of features to select (nFeats). Firstly, feature ranking was performed in
the training fold using the minimum-redundancy maximum-relevance (mRMR)
algorithm [70]. This method maximises the dissimilarity and minimises the re-
dundancy between features. To identify the hyperparameter nFeats, an inner
stratified 10-fold CV scheme was implemented within the training set. Data
was thus further split into training and test folds, and different sizes of features
sets were tested: nFeats = 3,5,10,20,30,40,50,60,70,80,90,100,150,200,250,254.
The AUC performance of each feature set when used with a logistic regression
(LR) classifier was recorded for each fold. The LR classifier was chosen for its
simplicity. The AUC was averaged for all folds of each feature set, and the
nFeatsi with the highest value was chosen as being optimal. This optimal num-
ber of features was then selected from the outer training fold data, and given
to train and test the model classifiers.
Pearson correlation between the top five features for the whole dataset was
also calculated.
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2.2.7 Classifiers
Parmar et al. [69] reported the Random Forest (RF) classifier to have ob-
tained the highest prognostic performance with high stability against data per-
turbations. However, LR is by far one of the most widely used classification
algorithms. Both algorithms are simple and computationally efficient, so the
performance of RF and LR classifiers was evaluated here.
The LR model was built using a l2-penalty, tolerance=0.0001 and C=1.
The RF model was built using 45 trees and a minimum of two samples per
split. As ours is an imbalanced dataset (i.e. more non-recurrent than recurrent
samples) for both classifiers the class weight was set to ‘balanced’ so that the
weights are adjusted to be inversely proportional to the class frequencies in
the input data. To investigate the stability of the RF model, the classification
process was repeated 20 times, and the standard deviation (SD) of the obtained
AUC values was calculated.
The stratified 10-fold CV was used to avoid overfitting by ensuring the test
set was independent and not included in the feature selection process. A sepa-
rate model was created for each of the ROIs and for both RF and LR classifiers,
resulting in a total of 4 imaging models. The clinical model was developed
using a LR classifier. A total of two combined models - using the predictions
from RF and LR imaging classifiers combined with clinical predictions - were
investigated per ROI.
Figure S2.1 (Supplementary Materials) illustrates the different steps in
optimising feature selection, in classification and cross-validation.
2.2.8 Statistics
To test for significant differences between clinical features of recurrent and non-
recurrent patients, a T-test (for continuous variables) and a chi-square test (for
categorical variables) was used. The patient’s clinical stage is decided in con-
sensus between the urologist and radiologist, and is therefore potentially biased
by the MRI findings. A bivariate Pearson correlation was calculated between
the TNM stage and all MRI extracted features. The degree of correlation can
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help reason as to whether the clinical TNM stage provides similar information
as the imaging features; if so, the two models cannot be considered to provide
independent predictions. The same correlation measure was performed between
Gleason score and the MRI extracted features.
2.3 results
Patient characteristics are reported in Table 2.2. The follow-up time was five
years or until biochemical recurrence. Median time to BCR was four years
(range 1-5 years). Three recurrences were local [10%], six were locoregional
[19%] (local with involved lymph nodes), two were regional [7%] (only lymph
nodes), three were regional-distant [10%] and 11 were distant (typically bone
metastasis) [35%]. For six [19%] recurrent patients the location was unreported.
Table S2.1 (Supplementary Materials) reports the distribution of recurrence
location according to T stage, Gleason score and PSA level. Recurrence loc-
ation was determined by either Choline or 68Ga-PSMA PET, SPECT/CT and
at times MRI and/or biopsy.
Figure 2.1 illustrates the segmented ROIs from which imaging features
were extracted. The original, as well as the resampled and filtered images
provided for feature extraction are presented in Figure 2.2 for a representative
patient.
No significant differences were found between the clinical variables of recur-
rent and non-recurrent patients (p-values were 0.40 for PSA, 0.14 for Gleason
and 0.62 for TNM stage) highlighting the clinical homogeneity of the high-risk
cohort. TNM stage and Gleason score were weakly correlated (maximum abso-
lute value of 0.30 and 0.35 respectively) with the MRI extracted features of any
of the ROIs. Thus, the clinical model was considered to provide an independent
prediction from the imaging models.
Table 2.3 shows the AUC values for the different classifiers; for RF, the
value is averaged over the folds and for 20 runs with the corresponding SD
between different runs. For a single run, using whole-prostate imaging features,
the average AUC (SD between folds) for 10 folds was for the RF classifier 0.56
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Table 2.2: Patient characteristics.
The numbers in brackets are the percentages rounded down to the nearest integer.
IQR – Interquartile range.
Recurrent Non-recurrent
Number of patients (%) 31 (26%) 89 (74%)
Median pre-treatment PSA
(ng/ml) [IQR]
17 [25] 15 [29]
PSA 6 10 9 (29%) 31 (35%)
10 < PSA 6 20 7 (23%) 17 (19%)
PSA > 20 15 (48%) 41 (46%)
Clinical tumour stage
T1 2 (6%) 10 (11%)
T2 9 (29%) 20 (22%)
T3 + T4 20 (65%) 59 (66%)
Primary Gleason grade
Gleason 5 - 6 6 (19%) 20 (22%)
Gleason 7 9 (29%) 31 (35%)
Gleason 8 9 (29%) 28 (31%)
Gleason 9 - 10 7 (23%) 10 (11%)
Figure 2.1: The different regions of interest (ROIs) used for feature extraction. The ROIs were
created by expanding (and in the case of the margin also shrinking) the original
delineations (thin lines) to obtain the final ROIs used for feature extraction (solid
lines).
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Figure 2.2: A. Original T2w image; B. Normalised and resampled image in the grid of 2 x 2
x 2 mm3; C – E Normalised and resampled images filtered with a Laplacian of
Gaussian (LoG) with sigmas = 1,3 and 5 mm. The resampled image as well as
the filtered images were used as input for feature extraction. The white contour
represents the prostate ROI.
(0.21) and 0.63 (0.18) for the LR. Margin imaging features obtained for a single
run of 10 folds an average AUC (SD between folds) of 0.57 (0.20) for the RF
classifier and 0.59 (0.21) for the LR.
The clinical model had a poor performance with an AUC (SD between folds)
= 0.51 (0.18). The best performance with imaging features was obtained for the
whole-prostate region with a LR classifier. The highest AUC for the combination
of imaging and clinical features was of 0.58, using margin imaging features.
The most prevalent optimal number of features was three for the margin,
and either three, ten or 20 for the prostate (all were chosen by three folds each).
There was inter-fold variability regarding the optimal number of features. For
the prostate, the optimal number of features varied between three [30%], 10
[30%], 20 [30%] and 90 [10%]. For the margin the values were of 3 [60%], 5 [20%],
30 [10%] and 60 [10%].
26 biochemical recurrence prediction after radiotherapy
22
Table 2.3: AUC values obtained with the different feature selection methods and classifiers.
Numbers in brackets show the standard deviation for average AUC for all folds




Imaging Imaging + Clinical
ROI mRMR + RF mRMR + LR mRMR + RF mRMR + LR
Prostate 0.55 (0.03) 0.63 0.54 (0.02) 0.56
Margin 0.56 (0.02) 0.59 0.58 (0.02) 0.54
Table 2.4: Feature ranking for the different ROIs obtained using the mRMR method for the
whole dataset.
Prostate Margin
#1 LoG sigma 3 GLRLM LGLRE No filter image first order 10th percentile
#2 No filter image first order minimum No filter image GLCM cluster shade
#3 LoG sigma 5 GLCM inverse difference normalised No filter image shape surface area
#4 LoG sigma 5 GLCM cluster prominence LoG sigma 5 first order maximum
#5 LoG sigma 5 first order mean LoG sigma 3 GLCM difference variance
Names and description of the highest ranking features for the two ROIs,
when ranked in the whole dataset, can be found in Table 2.4. The majority
of the top 5 prostate features originated from the filtered images and for the
margin from the no filter image. The LoG filter enhanced boundaries and overall
changes in intensities. First order statistics were mostly associated with ex-
treme values (e.g. minimum, maximum). Textural based features were related to
homogeneity (e.g. GLCM inverse difference moment normalised), heterogeneity
(e.g. GLCM difference variance and GLCM dissimilarity) as well as skewness,
asymmetry and uniformity of the GLCM (e.g. GLCM cluster prominence and
GLCM cluster shade). The highest Pearson correlation for the top five features
was 0.20 for the prostate and 0.51 for the margin.
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2.4 discussion
In this study we aimed at identifying high-risk PCa patients who are at a higher-
risk of BCR up to five years after EBRT. The heterogeneous outcome reported
in this homogeneously treated high-risk cohort raises the question of potential
treatment intensification for a subgroup of very high-risk patients. A LR model
with clinical features resulted in a poor performance predicting BCR. This is
not surprising as no significant differences were found between clinical features
of recurrent and non-recurrent patients, confirming the clinical homogeneity
of the cohort and highlighting the difficulty in discriminating patients solely
based on clinical information. Similar findings have been reported by Hegde
et al. [71], stressing the importance of imaging in such a high-risk cohort.
Literature reported values for the use of the Kattan nomogram are of AUC
= 0.61 [72] and 0.58 [62], higher than our clinical model performance. The
Kattan nomogram was originally developed using a combined population of
intermediate and high-risk patients and the literature values reported above
are obtained when applied in similarly mixed cohorts. We did not use the
original Kattan nomogram but instead a model incorporating the same features
and trained on our own clinically homogeneous cohort. Despite the differences
in methodology and cohort characteristics, our findings are in line with the
published literature.
Whole-prostate pre-treatment MRI radiomic features obtained an AUC of
0.63, outperforming standard clinical features in recurrence prediction. Several
studies describe the association between tumour adjacent stroma and prostate
microenvironment to relapse and disease progression [73, 74]. MRI is known
to have limited accuracy in the detection of small tumour foci of less than 0.5
cm3 [49]. Thus it is impossible to rule out the presence of satellite lesions,
not visible on MRI and missed by biopsy sampling, in the remaining prostatic
region. Analysis of the prostate as a whole is less time consuming and takes
into account all available information. The overall findings support the idea
that relevant information can be found on a whole-prostate level as well as the
potential of this region for BCR prediction. Due to the cohort’s clinical homo-
geneity, combining clinical with imaging features did not improve performance
and introduced noise.
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Despite the AUC values being relatively low to extrapolate significant clin-
ical decisions, these results offer a proof of concept of the potential of radiolo-
gical images in the context of precision medicine. Published literature on the
use of radiomics for outcome prediction reported similar AUC values [69, 75].
For our cohort with five years follow up, only T2w anatomical scans were avail-
able for all patients, whereas to date mp-MRI is considered standard of care
for diagnostics and treatment. Functional parameters extracted from DCE-MRI
and DWI have been found to be predictive of response in other cancer sites [76,
77] and in pre-clinical studies [78]. In particular, the association between DWI-
derived ADC maps and Gleason score has been extensively reported [79, 80].
The inclusion of functional imaging can potentially enhance the performance of
biochemical recurrence prediction models.
The MRI protocol underwent slight changes during the period in which
this patient cohort was treated. The influence of different MRI scanners, para-
meters and setup on the extracted radiomic features is still under-investigated.
Standardizing the extraction and use of radiomic features as well as evaluating
the repeatability of MR-based radiomic features are important subjects. Vari-
ous reviews [81, 82] highlight important topics to be addressed in designing
future radiomics studies. To tackle the curse of dimensionality we use a fea-
ture selection method, as commonly done in the radiomics field. Optimising an
RF classifier would be an alternative to regularise the model and address this
issue.
Lastly, the results obtained in this study require external validation in sim-
ilar cohorts, with our findings suggesting the use of a small number of features.
Nonetheless these are encouraging findings as they provide pilot evidence of
the relevance of imaging in outcome stratification of clinically homogeneous pa-
tients. The use of whole-prostate imaging characteristics to obtain information










where x and f(x) are the original and normalised intensities, µx and σx are
the ROI mean and standard deviation of the intensity values, and s is a scaling
value here set to 100. Intensity values outside three standard deviations from
the mean were considered outliers and set to µ + 3σ or µ - 3σ according to
their location in the distribution.
2.5.2 Feature scaling
All imaging features were scaled by subtracting the median and scaling the data
according to the interquartile range. This method provides increased robustness
against outliers which can impact the estimation of the mean and variance used
by typical scalers, and is implemented as a ‘robust scaler’ part of scikit-learn
– a machine learning toolbox for Python.
2.6 appendix b
The textural features homogeneity and informal measure of correlation were
calculated using two different formulations:
















informal measure of correlation 1 =
HXY −HXY1
max(HX,HY)
informal measure of correlation 2 =
√
1− e−2(HXY2−HXY)
Where Ng is the number of discrete intensity levels in the image and
therefore the size of the GLCM matrix; i and j are the elements from the matrix;
p is the second-order joint probability function of an image region constrained
by the mask; px is the marginal row probabilities; py is the marginal column
probabilities; HX and HY are the entropy of px and py; HXY is the entropy of
p(i,j) and





p(i, j)log2(px(i)py(j) + ε)






being ε an arbitrarily small non-negative number added to prevent log(0)
which is undefined (-infinity).
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2.7 appendix c
2.7.1 Programs and settings
All programming and analysis were performed in Python 3.5 and MATLAB
2017a. The simple Insight Segmentation and Registration Toolkit was used to
resample the images prior to feature extraction. An online available MATLAB
implementation of the mRMR method by Peng et al. [83] was used. Feature
scaling and the RF and LR classifiers were used as implemented in the scikit-
learn 0.18.1 package for Python [84]. Statistics were performed using IBM
SPSS Statistics 22.
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supplementary materials
Figure S2.1: Feature selection, classification and cross-validation pipeline. The stratified 10-
fold cross validation (CV) separates the patients in 10 folds, and then iterates the
use of 9 folds for training and the remaining fold as test set. Feature selection is
performed using stratified 10-fold CV on the training set where different subsets
of features are tested. Variable i = 1, 2. . . M, where M equals the total number of
nFeats combinations to test. The number of features resulting in the maximum
AUC value in the training set is used to train an LR and RF classifiers which are
evaluated on the remaining independent test fold. This process is repeated 10
times.
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Table S2.1: Recurrence location according to primary clinical tumour stage, Gleason grade
and pre-treatment PSA values.
Recurrence location
Local Locoregional Regional Regional-distant Distant
Clinical T stage
T1 - - - - 1
T2 - 3 - - 4
T3 + T4 3 3 2 3 6
Gleason grade
6 1 1 - 1 2
7 - 1 - 2 4
8 1 3 2 - 1
9 + 10 1 1 - - 4
Pre-treatment PSA (ng/ml)
PSA 6 10 1 2 - - 5
10 <PSA 6 20 1 - - 1 3
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abstract
Background and purpose: The introduction of a magnetic resonance (MR)-only
workflow in radiotherapy requires that fiducial markers, used for position veri-
fication, can be detected on MR images. Here we evaluate a model for marker
detection in prostate cancer patients by combining information from our hos-
pital standard multi-parametric (mp-) MRI protocol (T1-weighted - T1w, T2-
weighted - T2w, B0) with dedicated sequences (balanced steady-state free
precession sequence - bTFE, susceptibility weighted imaging - SWI).
Materials and methods: Thirty two patients scheduled for external-beam radio-
therapy received a mp-MRI and computed-tomography; the latter was used as
ground truth location of the markers. A logistic regression model was imple-
mented for marker detection by combining features from all imaging sequences.
The performance of the individual and combined sequences was assessed by
determining true and false positive detections.
Results: The combination of different sequences (mp-MRI) resulted in a better
performance than the best imaging sequence alone (bTFE). Combining mp-MRI
+ bTFE resulted in good accuracy and a true positive detection rate of 0.94.
Conclusions: The standard mp-MRI provides valuable information to detect fi-
ducial markers. The combination of different sequences outperforms the use of
a single dedicated sequence. We recommend the addition of a bTFE to the
standard mp-MRI protocol to improve fiducial marker detection.
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3.1 introduction
Prostate cancer patients scheduled to receive external-beam radiotherapy (EBRT)
are commonly implanted with fiducial markers used for treatment position veri-
fication. Currently, the markers are identified using computed-tomography (CT)
whereas structures are delineated on magnetic resonance imaging (MRI), re-
quiring registration of MRI to CT. The registration procedure is associated with
errors which will propagate throughout the whole treatment chain. The intro-
duction of a magnetic resonance (MR)-only workflow is a possible way to avoid
this. However, a precondition is the ability to identify the markers on MRI.
The most commonly used markers are made of gold, usually presenting as a
local signal void on MR images. Several studies have investigated the accuracy
of specifically optimised MRI sequences for the detection of implantable metallic
structures such as fiducial markers. Some suggest the use of optimised spin-
echo MRI sequences, improving void visibility [85], or gradient-echo sequences
[86, 87] sensitive to T2* decay, using the susceptibility effects to get better
marker depiction [88], as well as by combining it with contrast agents [89].
Others visually combine different MRI sequences [90, 91], while some groups
have developed sequences that allow for positive contrast at the marker [92–95].
Typically, patients receive a multi-parametric (mp-) MRI used for radio-
therapy (RT) target delineation as part of their standard clinical treatment.
In our hospital this protocol includes anatomical (T1- and T2- weighted) and
functional (diffusion-weighted (DWI) and dynamic contrast enhanced (DCE))
sequences as well as a B0 map acquired for the post-processing of DWI-MRI.
Sequence specific parameters result in distinctive marker voids between im-
ages, increasing the complexity of reproducible and accurate manual marker
localisation. We propose the development of a marker detection model using a
machine learning framework incorporating information from the clinical mp-MRI
protocol. To investigate the performance of some of the most often used dedic-
ated sequences we have incorporated a balanced steady-state free precession
sequence (balanced Turbo-Field Echo or bTFE) [86, 87] and a susceptibility
weighted imaging (SWI) sequence in the scanning protocol. Our goal is to in-
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vestigate the performance of a model based on the standard mp-MRI protocol
and compare it to models based on a single, dedicated sequence.
3.2 materials and methods
3.2.1 Dataset
Thirty two consecutive patients with biopsy proven prostate cancer, scheduled
to receive external-beam radiotherapy (EBRT) were treated between October
2015 and January 2016. Up to three gold fiducial markers (RT Cast, 1.0× 3
mm) were implanted per patient. Approximately 1 week after implantation, and
on the same day, patients underwent a mp-MRI and a CT scan used for RT
planning purposes.
The MRI data was acquired using a 3T Achieva dStream MRI scanner
(Philips Healthcare, Best, The Netherlands) with the use of an anterior and
posterior phased array coil. The mp-MRI protocol included transversal T1-
weighted (T1w) T1 THRIVE and T2-weighted (T2w) T2 turbo spin-echo (TSE)
images, B0 map, and the dedicated sequences bTFE and SWI (details of the
protocol can be found in Table S3.1, Supplementary Materials). Coronal and
sagittal T2w scans as well as functional sequences were also acquired as part of
the protocol but were not used for further analysis. The CT scans were acquired
using a 24-slice CT scanner (Somatom-Sensation-Open, Siemens), with image
resolution 0.9× 0.9× 3 mm3 (x, y, z).
A conservative threshold of 1900 Hounsfield units, resilient to possible
streaking artefacts, was used to segment the markers on the CT images. The
ground truth (GT) marker coordinates were automatically calculated as the
centre of mass of the clusters resulting from the segmented CT image. All MR
images were acquired within the same exam session. To account for possible
within-session motion all images were rigidly registered to the T1w scan with
the use of a clipbox around the prostate and periprostatic region [96]. Sub-
sequently the T1w scan was registered to the CT using a similarly defined
clipbox; the transformation was then applied to the other MRI sequences. This
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was achieved by means of rigid-registration (mutual information). Registra-
tion accuracy was checked by visual inspection of the prostate boundaries and
marker overlap and by assessing the registration error comparing the GT co-
ordinates with a manually defined centre of mass of the marker artefact in the
bTFE sequence (CMmbTFE). The difference between GT and CMmbTFE coordin-
ates was used as a measure for the target registration error (TRE) between CT
and MR.
The prostate gland was delineated using the T2w sequence. The ROI used
for model analysis was defined as a 4 pixels (3.6 mm) expansion of the prostate
delineation (Figure 3.1A-F). Within the ROI the signal intensities (SI) for each
image (T1w, T2w, B0 magnitude, bTFE and SWI images) were normalised to
values between 0 and 1 using Min-Max scaling, ensuring the values were
comparable between patients. All images were resampled to the grid of voxel
size 1× 1× 1 mm3.
3.2.2 MRI features and feature extraction
The markers present as signal voids in most MR images and their apparent
position depends on their shape and orientation relative to the magnetic field.
With exception of T2w, the artefact they induce is usually much larger than
the actual physical size and often exhibits a blob-like shape in T1w, bTFE, B0
magnitude and SWI images – Figure 3.1A-F. This same artefact also expands
through slices in a cylindrical line-like pattern. In this study we have included
multi-scale blobness [97] and line filtering [98, 99] of the prostate region as well
as intensity based local statistical features such as signal intensity in the voxel
i and the mean, median, minimum, maximum and standard deviation values from
a local window (3× 3× 9 voxels in x, y, z, directions, where z is along the B0)
surrounding this voxel.
Each voxel was described by 42 features in total (6 features from T2w and 9
features from each T1w, B0 magnitude, bTFE and SWI). Table 3.1 summarises
all extracted features with detailed description. Single sequence models include
all features extracted for that specific imaging sequence.
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Figure 3.1: Model pipeline in one representative slice. (A-F) CT and all MRI sequences. The
ground truth map (G) was constructed based on the information from the CT scan
and delineations. (H-J) Different model outcomes; all models correctly identify
the two markers present on this slice. Model results are prior to cluster selection.
Performance was investigated for models created using four sequence com-
bination options: 1) mp-MRI only (T1w, T2w and B0 magnitude); 2) mp-MRI +
bTFE; 3) mp-MRI + SWI and 4) mp-MRI + bTFE + SWI. Models for each indi-
vidual imaging sequence were also created in order to ascertain their individual
value.
3.2.3 Model creation
Ground truth maps (GTmaps) were created based on the GT coordinates, incor-
porating the prostate and margin delineations; these were used to train and
validate the model results.
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Data analysis was performed using MATLAB R2015a (MathWorks, Natick,
MA, USA) and the PRTools toolbox [100]. PRTools is a pattern recognition
toolbox that among others supports feature extraction, the use of classifiers
and evaluation methods. First, we determined from the GTmaps the value of
M, representing the average number of voxels labelled as markers. Then, for
each of the individual sequences and for the four sequence combinations a
model was trained by fitting a logistic regression to the labelled (marker or
non-marker) training data. The logistic regression model, applied to an unseen
dataset, results in a map of the probability for each voxel of being a marker.
The M highest probability voxels were grouped into clusters. We defined the
probability of each cluster candidate as the highest probability value of all
voxels within it. Prior information regarding the number of markers implanted
per patient was used to further post-process the results by selecting the n(j)
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highest probability clusters, where n(j) is the number of markers implanted in
patient j. Other than the logistic regression, the process did not involve any
optimization of parameters or feature selection.
Each model was evaluated using a leave-one-dataset-out cross-validation
method to make sure that the training set – used to build the model – and test
set are independent from each other. The different (individual and combination)
models were trained and the rate of true positives (TP) and false positives (FP)
was used to assess the performance of the model for each patient. Clusters were
classified as a FP if the distance between the GT coordinates and the centre
of mass of the clusters identified by the model (CMModel) was larger than 3mm
in plane or through slice. Model accuracy was assessed for each marker by
calculating the distance between the GT coordinates and the CMModel for all
TP.
3.2.4 Statistics
A Shapiro-Wilk test was used to test the normality of the TRE between MRI
and CT coordinates. For each model we determined the numbers of TP and
FP per patient and combined them into distributions over the population. A
non-parametric Wilcoxon signed-rank test was used to evaluate whether the
difference in distributions between models was statistically significant (p 6
0.05). Statistical analysis was performed using IBM SPSS Statistics 22.
3.3 results
For two patients air was present in the rectum which resulted in signal drop-off
around this boundary in the bTFE sequence, complicating the detection of two
markers (one in each patient) implanted in this region – Figure 3.2. Thirty
patients were implanted with three markers; in the remaining two only two
fiducial markers were implanted.
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Figure 3.2: Model pipeline in one representative slice. (A-F) CT and all MRI sequences. The
ground truth map (G) was constructed based on the information from the CT scan
and delineations. (H-J) Different model outcomes. One of the markers is visible
on T1w, T2w, B0 mag and marginally visible on SWI (filled arrow head) but not
on the bTFE sequence (open arrow head). This marker could not be identified on
the bTFE model; the mp-MRI and mp-MRI + bTFE models successfully detect the
two markers. Model results are prior to cluster selection.
Within-session motion between the different MRI sequences was also quan-
tified: median of translations in all images relative to T1w, averaged for the
population, were equal or less than 0.3 mm in all directions (interquartile range
[IQR]: 0.9–1.4); average median rotation (in degrees) was 0 in all directions (IQR:
0.4-0.7).
Two markers were not visible on the bTFE sequence and were therefore
excluded from the comparison between GT and CMmbTFE coordinates. The TRE
was not normally distributed, with median values of 0 mm for all directions and
IQRx,y = 1mm, and IQRz = 2mm – Figure 3.3A.
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3.3.1 Evaluation of model performance
Figure 3.1 (A-F) displays the acquired CT and MRI sequences for an example
patient and slice, as well as the respective GTmaps - Figure 3.1G - and model
results – Figure 3.1 (H-J).
Figure 3.3: A) Histogram of the registration errors (mm) between CT and MRI in x, y and z
directions; B) Accuracy of the mp-MRI + bTFE model in three spatial directions
(x, y, z). GT – ground truth marker location based on segmented CT image; CM
– center of mass of the cluster identified by the model. The plots represent the
differences between the two coordinates for each separate marker.
Based on the GTmaps, each patient had on average M = 103 (SD = 11)
voxels labeled as markers. Therefore clusters were formed by selecting the M =
100 highest probability voxels. In our dataset there were in total 94 implanted
markers. Table 3.2 lists the number of TP and FP. Cluster selection based on
the number of implanted markers per patient successfully reduced the number
of FP for all models. The number of TP was also reduced but by a lesser extent
than the FP. The number of false negatives (FN) can be inferred from the TP
and FP: when TP + FP = 94, FN is equal to FP; if TP + FP < 94, FN = 94
– TP.
The mp-MRI model correctly detected a total of 83 markers (FP = 10)
but with fewer positives than markers. The addition of the bTFE or SWI to
the standard mp-MRI model improved performance, resulting in a total of 88
and 87 TP, respectively. The single imaging modality model with highest true
positive rate (TP/P) was the bTFE (TPR = 0.77) – Table 3.2.
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Table 3.2: Model results. In white the model results using individual sequences and in grey
the results from the combined models.
† In total there are fewer positives (TP + FP) than markers
















T1- THRIVE 74 649 36 58 0.38 1.8
T2 TSE 41 1163 7 87 0.07 1.7
B0 mag 76 33 70† 20 0.74 1.9
bTFE 88 340 72 22 0.77 1.7
SWI 51 51 48† 25 0.51 2.0
mp-MRI 89 39 83† 10 0.88 1.6
mp-MRI + bTFE 93 32 88* 6* 0.94 1.6
mp-MRI + SWI 88 14 87* 6* 0.93 1.7
mp-MRI + bTFE + SWI 92 8 89* 4* 0.95 1.6
The combination of mp-MRI with a dedicated sequence improved marker
detection. The combination mp-MRI+bTFE resulted in a significantly better
performance (p = 0.005) than using the bTFE alone. The mp-MRI + bTFE
model accurately detected all markers for 26 out of 32 patients (81%), the mp-
MRI in 75% and the bTFE in only 47% of the patients.
Model accuracy was described in terms of the Euclidean distance between
the GT coordinates and the centre of mass of correctly identified markers
CMModel – Table 3.2. Figure 3.3B illustrates the distance distributions for
the markers detected by the mp-MRI+bTFE model, discriminated for the three
directions, where IQRx = 0, IQRy = 1 and IQRz = 2. Distances became smal-
ler by taking the registration error into account - removing this error from the
mp-MRI + bTFE model results decreased the standard deviation of the model
accuracy distribution. The manually selected CMmbTFE and the correctly iden-
tified marker location in the mp-MRI+bTFE model had mean deviations (mm)
of -0.49 ± 0.56 (x), 0.46 ± 0.58 (y), -0.24 ± 1.10 (z), median of 0 and IQRx,y =
1, IQRz = 2.
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3.4 discussion
Moving towards an MR-only environment will mitigate registration errors as
well as contouring inconsistencies [101–105]. A requisite for the implementation
of an MR-only environment in RT is the ability to identify prostate fiducial
markers on MRI. Manual marker detection represents a significant challenge
for accurate and reproducible marker centroid detection, is time consuming,
affected by pixel-size, noise, and quality of software used for detection [106].
We investigated the performance of MRI-based fiducial marker detection models,
using CT as the ground truth. Provided that a delineation of the prostate is
available - this is routinely performed and increasingly automated - the models
presented here are fully automatic.
In our study, the mp-MRI model performs significantly better than the best
imaging sequence alone (bTFE). The bTFE sequence has characteristics which
optimise its potential for manual marker detection such as high SNR and good
contrast, the markers presenting as small signal voids. However these same
characteristics also increase the complexity for automated methods, due to the
high similarity between a marker void and noise. In our detection setting the
bTFE sequence benefits from being combined with the standard mp-MRI.
Schieda et al. [88] described how multi-echo gradient recall sequences
might be of particular importance in the detection of markers located outside
of the prostate gland. We implemented a multi-echo SWI sequence which has
shown limited performance when used individually for automatic marker detec-
tion. The combination mp-MRI+SWI had good performance but a decreased
model accuracy when compared to other combined models. The large extent of
the artefact and its possible asymmetries when compared to the marker phys-
ical structure possibly compromised accurate localisation of the marker centroid.
Moreover the sequence’s long scanning times render it unpractical for clinical
implementation.
Although no statistically significant differences were found between the
mp-MRI and mp-MRI + bTFE models, the latter improves marker detection in
cases where the mp-MRI model has failed, decreasing also the total number of
FP. The mp-MRI + bTFE model has originally identified 93 markers; however
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some of them have been rejected in favor of confounders upon cluster selection.
Structural changes such as calcifications – found in over 40% of prostate cancer
patients [107] - can mimic the appearance of markers on MRI, resulting in
misclassifications. Fiducial markers implanted close to the rectum boundary
can be difficult to detect, specifically in the bTFE sequence in the presence
of air pockets in the rectum; in these cases combining different sequences can
increase the likelihood of detection. The inclusion of the bTFE sequence in the
clinical mp-MRI protocol has a minimal impact on scanning time (roughly two
extra minutes), enabling an accurate localisation of the marker centroid, which
is important for patient positioning and accurate dose delivery [106]. The use
of a high bandwidth (BW) sequence (Table S3.1) reduces possible geometric
distortions.
Validation of the results is non-trivial. Our framework is initially based
on a voxel-wise logistic regression model but the final results are obtained
after cluster selection. The region effectively occupied by the markers is signi-
ficantly smaller than the whole prostate. This disproportion between TP and
FP versus the total number of non-marker voxels, makes calculating sensitivity,
specificity and accuracy for the voxel-wise model uninformative in this setting.
Thus, results such as TP, FP and TPR are reported on a cluster level.
Distances between manual MRI-based coordinates (CMmbTFE) and mp-MRI
+ bTFE model results are very small and comparable to Ghose et al. [106]. The
apparent and actual marker positions on MRI have been reported to deviate
< 1mm at 1.5T [108]. MRI-CT registration errors are small (median = 0 mm)
with IQR up to 2 mm, well within reported literature values in this setting [96,
109–111]. Although larger deviations from the GT can be explained by rigid
registration errors, these do not fully describe the overall model inaccuracies.
Asymmetries (in shape and extent) of the artefact on MRI may explain some
of the discrepancies between CT and MRI. The MRI artefact is dependent on
marker size and orientation relative to the magnetic field [112], as well as
on sequence BW, with possible asymmetries arising in the frequency encoding
direction [108] and phase encoding direction for echo-planar imaging sequences
[113]. The 3 mm limit for TP acceptability was chosen to remove outliers
but not to be so restrictive given the size of the artefact. Reported IMRT
systematic positioning errors, obtained using 2D electronic portal imaging, are
approximately 1 mm with random variations from 0.9 to 4 mm in the three
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orthogonal directions [114–116]. Overall geometric accuracy of the system is
approximately 2mm [117]. Average accuracy of the mp-MRI+bTFE model is 1.6
mm.
Tokuda et al. [118] described fully automatic segmentation of fiducial frames
for needle placement in MRI-guided prostate biopsies, by using a 3D multiscale
line filter, but the method was not applied for gold fiducial marker detection.
Ghose et al. [106] have also used machine learning methods for automatic fidu-
cial marker detection using MRI. The authors use two dedicated gradient echo
sequences (T1 and T2*w) and a dataset of 15 patients to develop a template-
matching approach for marker detection. The described framework correctly
identified all markers in 67% of the patients, compared to 73% by manual de-
tection. Our mp-MRI+bTFE model has detected all markers for 81% of the
patients. Validation of the results in a totally independent cohort, possibly
even on a different scanner and field strength, would be useful to understand
to what extent the model is transferable.
Fully unsupervised automated patient set-up requires 100% marker detec-
tion efficiency. The results indicate that none of the models is yet capable of
doing so. A semi-automatic approach might be a valid solution, as the mp-MRI
+ bTFE model, prior to cluster selection, identifies all but one of the markers.
Manual intervention can be used to ensure that all three markers are correctly
identified in the case of missed or incorrect detection.
We have here evaluated an automatic fiducial marker detection framework
with the use of MRI images. The core images used in the build of this model
are part of the clinical RT planning protocol; the bTFE sequence is available in
the clinical setting for the majority of scanners. Further optimization of image
pre-processing (e.g. interpolation), extracted features and selection methods,
enhancing the differentiation between markers and biological phenomena, can
improve model performance. The overall findings show promise in the applica-
tion of automatic fiducial marker detection methods in an MR-only workflow.
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PART 2
Magnetic resonance imaging for the
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abstract
Background: Post-radiotherapy locally recurrent prostate cancer (PCa) pa-
tients are candidates for focal salvage treatment. Multi-parametric MRI (mp-
MRI) is attractive for tumour localisation. However, radiotherapy-induced tissue
changes complicate image interpretation. To develop focal salvage strategies,
accurate tumour localisation and distinction from benign tissue is necessary.
Purpose: To quantitatively characterise radio-recurrent tumour and benign ra-
diation-induced changes using mp-MRI, and investigate which sequences op-
timise the distinction between tumour and benign surroundings.
Study type: Prospective case–control.
Subjects: Thirty-three patients with biochemical failure after external-beam
radiotherapy (cases), 35 patients without post-radiotherapy recurrent disease
(controls), and 13 patients with primary PCa (untreated).
Field Strength/ Sequences: 3T; quantitative mp-MRI: T2-mapping, ADC, and
Ktrans and kep maps.
Assessment: Quantitative image-analysis of prostatic regions, within and between
cases, controls, and untreated patients.
Statistical Tests: Within-groups: non-parametric Friedman analysis of variance
with post-hoc Wilcoxon signed-rank tests; between-groups: Mann–Whitney
tests. All with Bonferroni corrections. Generalised linear mixed modelling to
ascertain the contribution of each map and location to tumour likelihood.
Results: Benign imaging values were comparable between cases and controls
(P = 0.15 for ADC in the central gland up to 0.91 for kep in the peripheral
zone), both with similarly high peri-urethral Ktrans and kep values (min−1) (me-
dian [range]: Ktrans = 0.22 [0.14–0.43] and 0.22 [0.14–0.36], P = 0.60, kep =
0.43 [0.24–0.57] and 0.48 [0.32–0.67], P = 0.05). After radiotherapy, benign
central gland values were significantly decreased for all maps (P 6 0.001) as
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well as T2, Ktrans, and kep of benign peripheral zone (all with P 6 0.002). All
imaging maps distinguished recurrent tumour from benign peripheral zone, but
only ADC, Ktrans, and kep were able to distinguish it from benign central gland.
Recurrent tumour and peri-urethral Ktrans values were not significantly differ-
ent (P = 0.81), but kep values were (P 6 0.001). Combining all quantitative
maps and voxel location resulted in an optimal distinction between tumour and
benign voxels.
Data Conclusion: Mp-MRI can distinguish recurrent tumour from benign tissue.
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4.1 introduction
One of the main treatment options for localised prostate cancer (PCa) is external-
beam radiotherapy (EBRT). Depending on the risk-group, 5-year disease free
survival varies from 67 to 80% for PCa patients who are treated with whole-gland
radiotherapy (RT) to 78 Gy [58]. A small but significant proportion of patients
failing the primary treatment, will harbour locally recurrent disease only [26, 27],
for which focal treatment strategies, targeting the tumour region while sparing
the surrounding uncompromised tissue, might offer a curative treatment option.
To this end, multi-parametric magnetic resonance imaging (mp-MRI) with both
anatomical and functional properties is attractive for loco-regional evaluation of
recurrent PCa and for tumour boundary definition. However, RT-induced tissue
changes pose a challenge to MRI interpretation. T2-weighted (T2w) MRI is
the reference anatomical sequence, however it has limited performance in this
setting as tumour conspicuity is decreased and zonal anatomy is often lost [37].
The use of functional sequences such as 1.5T MR spectroscopy [45] as well as
diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE)-MRI
[38–40] were found to surpass T2w-MRI in the detection of recurrent disease.
To successfully develop focal salvage strategies for recurrent PCa, an accur-
ate detection and localisation of the tumour as well as distinction from radiation
affected benign tissue is necessary.
The objectives of this study were to: 1) investigate RT-induced tissue
changes and how these impacted the distinction of recurrent tumour from sur-
rounding benign tissue; and, 2) use quantitative sequences to characterise both
benign tissue and recurrent PCa after RT, and investigate which sequences
resulted in optimal tumour localisation.
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4.2 materials and methods
4.2.1 Patient Recruitment and Matching
This prospective single-institution study was approved by the Institutional Re-
view Board and took place between December 2015 and July 2018. All patients
signed informed consent prior to participation in the study. An overview of the
study design can be seen in Figure 4.1.
Figure 4.1: Study design with an overview of the three analysed cohorts. BCR, biochemical
recurrence; bx, biopsy; EBRT, external-beam radiation therapy
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Cases (patients with recurrent PCa)
Patients with a biochemical recurrence according to the Phoenix definition [65],
were enrolled in the study. Patients could only be included more than 24
months after completion of EBRT and if they qualified for salvage treatment. A
gallium-68 prostate-specific membrane antigen positron emission tomography
(68Ga-PSMA-PET) scan was acquired to exclude metastatic disease. Exclusion
criteria were hormonal therapy in the past year, the use of anticoagulants that
could not be stopped temporarily to acquire biopsies, contra-indications for an
MRI exam and other treatments for cancer in the pelvis. Patients received a mp-
MRI. When a tumour suspected region was identified, an MR-fused ultrasound-
guided biopsy was performed targeting this region. If no tumour suspected
region could be identified, either only prostate-specific antigen (PSA) follow-
up would be continued or a standard systematic biopsy could be performed. This
decision was made by the treating physician. Patients with positive imaging
and biopsy findings for locally recurrent PCa constituted the cohort of case
patients.
An inconclusive diagnosis was given to patients for whom a local or metastatic
recurrence could not be detected on MRI, or the biopsies were negative or both.
These patients were analysed further but separately from the cohort of cases.
Controls (patients without recurrent PCa)
Matched controls (patients without evidence of recurrent disease) were recruited
and received a mp-MRI scan. The matching criteria were: time since primary
RT (years), use of hormonal therapy and the risk group of the primary tumour.
Risk stratification was based on the definition proposed by the European As-
sociation for Medical Oncology (ESMO) in 2010 [119], incorporating changes
suggested in the review by Rodrigues et al. [120] on the importance of the
amount of high-grade cancer, differentiating between Gleason 3+4 and 4+3.
Risk stratification was defined as: low-risk - T1-T2a, Gleason 6 6 and PSA
6 10 ng/ml; intermediate-risk – T2b-T2c, Gleason = 7 (3+4) and PSA 6 20
ng/ml, not otherwise low-or high-risk; high-risk - T3-T4 or Gleason > 7 (4+3)
or PSA >20 ng/ml. The exclusion criteria were identical to those applied for
the cases.
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If a patient developed a biochemical recurrence during the study period, he
was moved to the inconclusive cohort.
Untreated (patients at primary diagnosis)
A previously reported cohort of 13 primary PCa patients [121, 122], scanned
prior to treatment with a mp-MRI protocol, was used as reference. As part of the
study, these patients underwent two mp-MRI scanning sessions. Following the
second MRI examination, the patients were treated with a radical prostatectomy.
This cohort is referred to as the untreated cohort.
4.2.2 MRI Protocol
All patients were scanned in a 3T Achieva dStream (A) or Ingenia (B) scanner
(Philips Healthcare, Best, The Netherlands). Twenty patients were scanned in
system A with a 6-channel cardiac coil and 48 were scanned in system B with
a 16-channel anterior and 12-channel posterior coil. With the exception of 4
patients (3 scanned in system A), all were scanned with the use of an endorectal
coil.
The mp-MRI protocol consisted of an axial, sagittal and coronal T2w turbo
spin echo; a 3D gradient echo T1-weighted (T1w); a balanced steady-state free
precession (bSSFP); an axial multi-echo spin echo k-t-T2 sequence [121], with
twelve echoes acquired at a spacing of 16ms, starting at 32ms; a transversal
diffusion weighted sequence (DWI) and a dynamic contrast-enhanced sequence
(DCE). DWI was acquired using a single-shot spin-echo echo-planar imaging
sequence with diffusion encoding b-values ranging from 0 to 800 sec/mm2. DCE
was acquired with a 3D T1w spoiled gradient echo sequence at a temporal
resolution of 2.6 seconds over 5 minutes, before, during and after intravenous
administration of 15 ml of Dotarem (0.5 mM Dotarem, Guerbet, Roissy CDG,
France). The contrast agent was administered using a power injector (MedRad,
Warrendale, PA, USA), followed by a 30 ml saline flush at a flow rate of 3 ml/sec.
Further sequence specific details can be found in Table S4.1 (Supplementary
Materials).
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Apparent diffusion coefficient (ADC) maps were derived from the DWI se-
quence using b = 200 and 800 sec/mm2. The standard Tofts model [123] was
used to calculate the pharmacokinetic maps Ktrans and kep. This was done using
a T1 map generated based on the variable flip angle method [124], using flip
angle = 3 ◦, 6 ◦, 10 ◦, 20 ◦, and 30 ◦, to convert signal intensity into concen-
tration, and an arterial input function (AIF) with parameters derived from an
in-house study population. T2 maps were created by converting the signal to
the logarithmic scale and performing a weighted linear fit.
All sequence-derived functional maps were generated using MATLAB R
2017b (Mathworks, Natick, MA, USA).
Visual inspection was used to assess possible displacements between the
functional sequences (and respective quantitative maps) and the T2w-MRI scans.
Rigid registration based on mutual information was used whenever necessary
to correct for these displacements. All images were resampled to the T2w grid.
Figure 4.2: Illustration of the delineated ROIs. In the left image the eroded prostate contour,
the peripheral zone, and the tumour can be seen delineated on the transversal T2w
image. On the right, the peri-urethral contour is presented overlaid on the sagittal
T2w scan.
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4.2.3 Region of Interest (ROI) segmentation
The prostate, the peripheral zone (PZ), the central gland (CG) and the region
surrounding the urethra – peri-urethral tissue (PU) – were delineated. The PU
region was delineated using both the sagittal and transversal T2w images. The
tumour suspected regions were delineated by a radiologist (14 years of experi-
ence) based on the MRI, PET and biopsy report information. As the Prostate
Imaging Reporting and Data System 2 (PI-RADS v2) [42] is not applicable
to recurrent prostate cancer, tumour was defined as a region with low signal-
intensity (SI) on T2w-MRI, high SI in the b=800 DWI scan, low SI on the ADC
map, and increased enhancement in the Ktrans and kep maps. For the untreated
cohort tumour delineations were originally performed on the histopathology and
propagated to imaging. Figure 4.2 illustrates the ROIs as delineated for a case
patient.
The bSSFP sequence was used to identify and exclude from further ana-
lysis the implanted fiducial markers. Prostate delineations were eroded in all
directions by 1mm to ensure that only prostate tissue was analysed.
Region of interest (ROI) analysis was performed using Python 3 (Python
Software Foundation, Delaware, United States).
4.2.4 Statistics
A t-test for continuous variables (PSA) and a chi-square test for categorical
variables (Gleason and TNM stage) were used to compare the clinical charac-
teristics of the cohorts.
Normality was checked using the Shapiro Wilk test. In a case of non-
normality a non-parametric Friedman’s ANOVA for dependent groups was used
to compare the different regions within the groups (untreated, cases and con-
trols). If significant, the differences were further evaluated using a post-hoc
Wilcoxon signed-rank test. To compare the same region between groups, a
Mann-Whitney test was used. To correct for multiple testing, a Bonferroni
correction was applied to the significance level of α = 0.05.
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Univariate and multivariate generalised linear mixed-effect modelling (GLMM)
was applied to assess the predictive value of imaging on the voxel-wise like-
lihood of tumour. Only case patients were used in this analysis. Voxels were
grouped into benign (resulting from a combination of unaffected PZ and CG)
and tumour (based on the radiologist delineations). To obtain the likelihood of
tumour on a voxel level, fixed and random effects were included. The quantit-
ative imaging maps and voxel anatomical location (PZ or CG) were accounted
as predictive variables and therefore included as fixed effects. Random effects
accounted for spatial clustering by incorporating voxel location within the pro-
state (the relative distance in x, y and z from the prostate centre of mass) and
patient identifiers. When the association between model parameters and tu-
mour probability was non-linear, the parameters were grouped in quartiles and
regression coefficients were estimated for each group considering the first quart-
ile as reference. The model fit was assessed using the Bayesian Information
Criterion (BIC) (a decrease of 10 points reflects an improved fit) and by evalu-
ating the residual random error. Statistics were performed with the Statistical
Package for Social Sciences, version 22.0 (SPSS, Chicago, IL, USA). Analysis
was performed in R [125] using the lme4 package [126].
4.3 results
4.3.1 Patient Characteristics
In total, 33 case patients and 35 controls were prospectively included in the
study. Adjuvant hormonal therapy was given for a maximum period of 3 years
to 82% of the cases and to 94% of the controls upon the treatment of primary
PCa. However, none of the patients received hormonal therapy within 1 year
prior to the MRI exam.
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Cases (patients with recurrent PCa)
Ten of the 33 included patients had either regional metastases without evidence
of intraprostatic recurrence (n=5) or an inconclusive diagnosis (n=5). Twenty-
three patients remained that fitted all the inclusion criteria for cases. For 3 of
the 23 case patients, the first biopsy was negative and a repeated navigated
biopsy confirmed the MRI suspected tumour location.
In 2 out of 23 patients the k-t-T2 sequence was not acquired and for another
the ADC map was not used due to poor image quality.
For the 23 cases a total of 27 suspected tumour foci were delineated, with
an average tumour volume of 1.37 cm3. From these, 4 were located in CG. The
median time to recurrence for the 23 cases was 7 years since primary EBRT
treatment.
Controls (patients without recurrent PCa)
One patient was initially recruited as a control but had a biochemical failure
during the study period. This patient was moved to the inconclusive cohort. The
remaining 34 matched controls (patients without evidence of locally recurrent
PCa) had a median time of 6 years since the EBRT treatment.
Untreated (patients at primary diagnosis)
The 13 untreated patients had a median time of 20 (range, 5-65) days between
the MRI and prostatectomy. None of these patients received hormonal therapy
before imaging. For one patient, the small dimensions of the histopathological
tumour resulted in a sub-voxel tumour ROI in MRI. For this patient only benign
tissue was analysed.
Table 4.1 describes the patient characteristics for cases, controls and un-
treated patients. For the untreated patients, the characteristics reported in the
table are based on the biopsy report and clinical TNM stage.
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The clinical characteristics of the cohorts were compared. TNM stage
was grouped in two (T1+T2 and T3+T4) and the Gleason score in three
groups (Gleason 6 6, 7, >8). Cases and controls had comparable clinical
characteristics (PSA: p=0.789; TNM stage: p=0.393; Gleason score: p=0.271).
Both case and control patients had significantly higher-risk primary PCa when
compared with the untreated patients (PSA: p=0.008 and p=0.003; TNM stage:
p=0.004 and p<0.001; Gleason score: p=0.03 and p=0.004 for cases and con-
trols, respectively).
Figure 4.3 illustrates the values of T2, ADC, Ktrans and kep for untreated,
controls, and case patients. Median imaging values for the 3 cohorts are presen-
ted in Table 4.2.
Table 4.1: Patient characteristics. Recurrent tumours were not assigned a Gleason score as
radiation induced atypia can be a confounder for pathological interpretation.
* In six case patients TNM stage of recurrent tumour was not reported
† For one case patient only the Anderson score (=2) was available
‡ In one case and one control the PSA of the primary tumour could not be retrieved
Cases Controls Untreated
Primary tumour Recurrence Primary tumour Primary tumour
TNM stage *
T1 - - 5 5
T2 11 13 6 7
T3 11 4 23 1
T4 1 - - -
Gleason score †
6 6 4 - 6 7
7 12 - 12 6
> 8 6 - 16 -
PSA (ng/ml) ‡
6 10 10 22 11 12
10 <PSA 6 20 6 1 14 1
> 20 6 - 8 -
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Figure 4.3: Boxplots with median values for all regions, imaging modalities, and the three co-
horts of patients: untreated, controls (non-recurrent), and cases (recurrent). Edges
of the boxes are the first (25th) and third (75th) quartiles, and whiskers represent
the 5th and 95th percentile. PZ, peripheral zone; CG, central gland; PU, peri-
urethral tissue.
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Table 4.2: Quantitative imaging values for the three cohorts in the different prostatic regions.
Median of all individual patients’ median values, with the minimum and maximum
presented between brackets.
PZ CG Tumour PU
T2
(ms)
Untreated 129 (67-258) 97 (81-114) 85 (70-128) 94 (84 - 135)
Controls 93 (76-129) 79 (66-99) - 92 (77-121)
Cases 91 (80-114) 79 (70-94) 81 (66-97) 91 (77-103)
ADC
(x10−3 mm2/s)
Untreated 1.40 (0.70-1.90) 1.20 (1.10-1.50) 1.00 (0.70-1.60) 1.32 (1.20 - 1.80)
Controls 1.32 (0.06-1.57) 1.20 (0.07-1.44) - 1.41 (0.07-1.70)
Cases 1.28 (0.45-1.51) 1.14 (0.52-1.32) 0.95 (0.41-1.29) 1.40 (0.67 - 1.62)
Ktrans
(min−1)
Untreated 0.16 (0.08-0.41) 0.29 (0.14-0.42) 0.29 (0.17-0.70) 0.28 (0.13-0.51)
Controls 0.11 (0.06-0.17) 0.15 (0.10-0.26) - 0.22 (0.14-0.36)
Cases 0.11 (0.05-0.16) 0.14 (0.08-0.24) 0.22 (0.09-0.40) 0.22 (0.14-0.43)
kep
(min−1)
Untreated 0.63 (0.32-1.20) 0.85 (0.31-1.18) 0.73 (0.39-3.89) 0.50 (0.26-0.96)
Controls 0.33 (0.17-0.49) 0.37 (0.26-0.58) - 0.48 (0.32-0.67)
Cases 0.32 (0.19-0.48) 0.36 (0.24-0.49) 0.58 (0.40-1.36) 0.43 (0.24-0.57)
4.3.2 Characteristics of irradiated benign tissue
Figure 4.4 illustrates the quantitative maps and suspected tumour regions for
a representative case (Figure 4.4A) and control (Figure 4.4B) patients.
The values for benign PZ and CG were comparable between cases and
controls (P = 0.15 for ADC in the CG up to 0.91 for the kep in the PZ). Values
in the PU were also similar between the groups (with the lowest P = 0.05 for
kep > 0.05/3). Both cases and controls presented with PU enhancement.
For controls, significant differences were found between PZ and CG and
between CG and PU (P < 0.001 for all comparisons between imaging values
and regions).
The values obtained for the PZ, CG and PU in the inconclusive cohort were
not significantly different from those of the cases (with the lowest P = 0.03 for
T2 in the PZ > 0.05/3) or controls (with the lowest P = 0.04 for T2 in the CG
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> 0.05/3). The quantitative imaging values for this specific cohort are present
in the Table S4.2 (Supplementary Materials).
Figure 4.4: Representative example of a case (A) patient with recurrence and a control (B)
without recurrent disease, with all anatomical and functional maps. Thin and
thick white lines represent prostate and tumour delineations, respectively. Black
and white arrows in the Ktrans maps point to the increased enhancement in the
peri-urethral tissue, present in both cases and controls.
4.3.3 Radiation-induced changes
To investigate radiation-induced tissue changes, the values from the untreated
patients were used as a population reference against which the values of the
cases were compared.
The different prostate regions were more homogeneous after RT and the
range of values was in general smaller than before treatment. With the excep-
tion of ADC (for which P = 0.03 > 0.05/4), T2, Ktrans and kep values in the PZ
were significantly lower (T2, kep P < 0.001 and Ktrans P = 0.002) after RT. The
CG imaging values were for all maps significantly lower after RT (all with P 6
0.001). In the PU, despite the higher Ktrans values seen before treatment, the
imaging values for all maps remained comparable before and after treatment (P
= 0.19 for T2 up to P = 0.56 for ADC).
Similar characteristics were seen for all maps for recurrent and primary
tumours (P = 0.17 for kep up to P = 0.22 for ADC).
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4.3.4 Tumour localisation
To compare recurrent tumour with the remaining irradiated benign gland, the
cohort of case patients was assessed. With all imaging maps, median tumour
values were significantly different from benign tissue within the PZ (P < 0.001
for all imaging modalities). No differences were seen between the T2 values of
suspected tumour and benign CG tissue (P = 0.08). However, values of ADC,
Ktrans and kep from suspected tumour regions were significantly different (all
with P < 0.001) from those of the CG. When compared with the surrounding
benign tissue, heightened Ktrans and kep values were seen in the PU. The PU
Ktrans values were comparable with those of suspected tumour (P = 0.81), but
with kep a significant distinction (P < 0.001) could be made between the two
regions. The PZ and CG ROIs were significantly different for all maps except
kep (P = 0.05 > 0.05/6).
Table 4.3: Model parameters obtained when combining T2 map, ADC, Ktrans and kep imaging
values to predict tumour at the voxel-wise level. Imaging values and location are
included as fixed effects; patient and spatial coordinates as random effects.
Fixed effects (MRI) Regression coefficients (β) Std. Error P
T2 map reference group (24 – 73) 0 - -
T2 map 2nd quartile (74 – 83) 0.08 0.01 <0.001
T2 map 3rd quartile (84 – 97) -0.40 0.01 <0.001
T2 map 4th quartile (98 – 1188) -1.50 0.02 <0.001
ADC -2.86 0.02 <0.001
Ktrans 6.52 0.09 <0.001
kep 4.85 0.04 <0.001
Location -0.98 0.01 <0.001
Intercept (β0) -5.55 0.46 <0.001





Residuals (ε0) Median First quartile Third quartile
-0.07 -0.13 -0.03
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Figure 4.5: A reconstructed probability map based on the generalised linear mixed model
(A). In red, overlaid on the T2w scan (B), is the same probability map threshol-
ded at 0.5 and in (C), in yellow, the original tumour delineation. The anatomical
and functional maps are presented in (D), together with the prostate and tumour
delineations in white.
Using the GLMM, we observed that univariately all MRI parameters were
significantly associated with tumour likelihood (P < 0.001). Location within the
gland was also significantly associated with tumour likelihood. The association
between T2 and tumour probability was non-linear, and therefore this parameter
was grouped in quartiles with univariate regression coefficients β = 0 (reference
group), 0.19, -0.59 and -1.83. The regression coefficients were for ADC: β = -
5.06, Ktrans: β = 17.27, kep: β = 8.42 and location: β = -0.64. The multivariate
model combining all mp-MRI parameters and location obtained the best fit and
was the most predictive for tumour likelihood (BIC of 392212, P < 0.001). The
values for the regression coefficients and standard errors are presented in Table
4.3. A reconstructed probability map for a case patient is presented in Figure
4.5.
4.4 discussion
In this study mp-MRI was used to quantitatively describe and distinguish be-
nign prostate tissue from recurrent PCa after RT. The use of two patient cohorts,
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with and without recurrent PCa, allowed us to show that tumour unaffected
areas were similar in both groups. Compared with the pre-treatment setting,
and with exception of ADC in the PZ, all other imaging values (T2, Ktrans and
kep) were lower, but also more homogeneous between the PZ and CG. This
is in agreement with literature describing the loss of zonal distinction in the
post-RT setting [37]. Still, significant differences between the imaging values
of PZ and CG were seen in both recurrent and non-recurrent patients. As in
primary disease, recurrent tumour occurred predominantly in the PZ. This is
not surprising as recurrence usually happens at the site of primary PCa [55].
For all maps, values of recurrent tumour were not significantly different from
those of primary PCa.
With all imaging maps, we found that the PZ was significantly different
from recurrent tumour, illustrating that all quantitative maps seem to have po-
tential to distinguish tumour in this region. However, tumour detection in the
CG is challenging using solely the T2 map, as the values for benign CG and
tumour are not significantly different. This distinction is possible when evalu-
ating ADC, Ktrans and kep. The PI-RADS v2 [42] is the standard radiological
guideline for the diagnose of primary PCa. These guidelines do not apply to the
detection of suspected recurrent PCa following treatment. Yet, in the absence
of further guidance, PI-RADS v2 is often used as a starting point for image
assessment. The guideline describes T2w as the dominant mp-MRI sequence
for the diagnosis of primary PCa in the transition-zone. Our results suggest
this sequence is of less relevance compared to the other mp-MRI sequences
when diagnosing recurrent PCa in this region. The results also suggest that
DCE-MRI has an important role in the diagnosis of recurrent disease. In non-
irradiated prostate tissue, the presence of benign prostatic hyperplasia (BPH)
in the central gland is an important imaging confounder for the use of DCE-MRI
in this region. In a previous study, pathology slides from salvage prostatectomy
specimens of recurrent PCa patients after radiotherapy were registered to mp-
MRI acquired prior to the surgery. In the analysed pathology, no BPH could
be found [127]. This suggests that BPH vanishes after radiotherapy. The en-
hancement in the peri-urethral area remains and needs to be considered. It has
been hypothesised that the fibrotic changes observed in irradiated prostates
[128] and the decreased microvasculature associated with atrophic tissue, en-
hance the neovascularity of recurrent tumour relative to the remainder benign
atrophic tissue [43].
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With overall median values below 100ms, T2 is decreased for the prostate
as a whole after RT. Measured T2 values (ms) were in agreement with a previous
study observing the effects of RT in prostate tissue [129] (at week 8 of the RT
treatment, mean ± SD: PZ = 89 ± 13, CG = 76 ± 5, Tumour = 75 ± 9) and
they provide evidence that the PZ and CG values do not increase after these 8
weeks.
The ADC values (in x 10−3 mm2/sec) obtained for recurrent tumour were
similar to those reported in other studies (mean ± SD: 1.0 ± 0.1 and 0.98 ±
0.23) [130, 131]. Tumour values in the untreated cohort were also comparable to
those previously described (tumour PZ, mean ± SD: 1.08 ± 0.39) [132]. Values
for benign prostate tissue in our case and control cohorts were slightly lower
than those reported by others (mean ± SD: 1.6 ± 0.2 and 1.60 ± 0.21; x10−3
mm2/sec) [130, 131]. We note that these studies did not distinguish PZ from
CG and reported values for a composite of both regions. In our untreated cohort,
benign prostate tissue showed slightly lower values than those seen by Sato
et al. (mean ± SD: 1.80 ± 0.41 for PZ and 1.58 ± 0.37 for the transition-zone)
[132].
In controls the PU region exhibited high Ktrans and kep values without
signs of malignancy. Similar high values were found in cases and this en-
hancement strongly overlapped with tumour values, which might represent a
confounder for tumour detection in the CG. Yet, with kep significant differences
were seen between tumour and PU, suggesting this could be a relevant para-
meter when assessing the CG. This effect has been previously described in the
recurrent setting [38, 44], potentially as a result of remaining BPH or peri-
urethral vasculature. Donati et al. [46] found no additional benefit of DCE
when complementing T2w and DWI, which could have been the result of benign
CG enhancement.
The GLMM analysis revealed tumour distinction was optimised with the use
of mp-MRI, highlighting the importance of using a combination of anatomical
and functional sequences when identifying and localizing tumour for salvage
treatment strategies. Our study did not include spectroscopic data. Nonethe-
less, spectroscopic data has been suggested as a valuable tool for recurrent
tumour distinction [130].
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Quantitative tissue characterization enables a more straightforward com-
parison between subjects, studies and centres. It also conveys important in-
formation to adapt the scanning protocols to better image this study population.
As an example, for patients with suspected recurrence, the sampling echo times
for T2 mapping should be shortened as T2 decay is expected to be shorter
compared to untreated patients.
We aimed to circumvent the limitations of a 2D standard transrectal ul-
trasound (TRUS)-guided systematic biopsy by using a 3D MRI-TRUS fusion
approach to target the tumour suspected region. With this technique’s improved
spatial information, it has been described that fewer cores were necessary to
detect more clinically significant cancer [133], often leading to reclassification
of primary tumours in higher risk categories [134]. Nonetheless, for a subset of
our patients, cancer was only confirmed with repeated biopsy. Even when nav-
igated, the biopsy procedure is limited by possible co-registration errors and in
delivering the biopsy needle to the intended point [135]. Tumour delineations
performed using 1.5T T2w, were shown to underestimate the true tumour volume
when compared with prostatectomy samples [55]. As a result, the detection rates
of MRI-TRUS fusion biopsies might also be affected by errors in defining the
lesion to target.
Our study has several limitations. Firstly, it was a single hospital study
with a limited number of patients. The controls were recruited to match the char-
acteristics of cases as best as possible, and no significant differences were seen
between their clinical parameters. However, our cohort of cases and controls
had significantly higher-risk primary PCa when compared with the untreated
patients. Thus, the reported imaging differences for benign tissue could the-
oretically arise from baseline imaging dissimilarities. No significant imaging
differences were seen between the tumours in the untreated and recurrent co-
horts.
Ideally, using salvage prostatectomy specimens as the standard of reference
would be preferred to accurately identify cancer location, but this procedure is
only sporadically performed. Thus, patients with an inconclusive diagnosis
were analysed separately to avoid a potential bias. The diagnosis of recurrent
disease is in practice made with a combination of mp-MRI and PSMA-PET
findings. In this study we opted to individually investigate the properties of
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MRI which, due to its higher spatial resolution, is better suited for the purpose
of tumour localisation. A combination of both modalities can certainly help
better select patients suitable for salvage treatment. Lastly, our GLMM was not
tested in an independent cohort. Thus further validation is required to establish
applicability to other populations. The model is also potentially reflecting
delineation practices.
In conclusion, tumour unaffected areas were similar between recurrent and
non-recurrent patients, and generally with lower and more homogeneous values
than before RT. The PU region presents with increased enhancement in the phar-
macokinetic maps for both cases and controls. Analysis of mp-MRI, with the
quantitative maps T2, ADC, Ktrans and kep together with location information
resulted in optimal distinction between tumour and benign voxels. The ability
to accurately localise tumour and distinguish it from benign tissue with the
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Table S4.2: Median of all patient’s median values for each region and imaging sequence for






84 (76 - 100) 70 (62 - 82) 83 (76 - 111)
ADC
×10−3 mm2/s
1.31 (1.20 - 1.48) 1.13 (1.03 - 1.36) 1.39 (1.16 - 1.68)
Ktrans
min−1
0.09 (0.04 - 0.12) 0.14 (0.08 - 0.24) 0.19 (0.12 - 0.25)
kep
min−1
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abstract
Objectives: Diagnosis of radio-recurrent prostate cancer using multi-parametric
MRI (mp-MRI) can be challenging due to the presence of radiation effects. We
aim to characterise imaging of prostate tissue after radiation therapy (RT), us-
ing histopathology as ground truth, and to investigate the visibility of tumour
lesions on mp-MRI.
Methods: Tumour delineated histopathology slides from salvage radical prosta-
tectomy patients, primarily treated with RT, were registered to MRI. Median
T2-weighted, ADC, Ktrans and kep values in tumour and other regions were
calculated. Two radiologists independently performed mp-MRI-based tumour
delineations which were compared with the true pathological extent. General
linear mixed-effect modelling was used to establish the contribution of each
imaging modality and combinations thereof in distinguishing tumour and be-
nign voxels.
Results: Nineteen of the twenty-one included patients had tumour in the avail-
able histopathology slides. Recurrence was predominantly multifocal with large
tumour foci seen after external-beam radiotherapy, whereas these were small
and sparse after low-dose-rate brachytherapy. MRI-based delineations missed
small foci and slightly underestimated tumour extent. The combination of T2-
weighted, ADC, Ktrans and kep had the best performance in distinguishing tumour
and benign voxels.
Conclusions: Using high resolution histopathology delineations, the real tumour
extent and size was found to be underestimated on MRI. Mp-MRI obtained the
best performance in identifying tumour voxels. Appropriate margins around the
visible tumour suspected region should be included when designing focal sal-
vage strategies. Recurrent tumour delineation guidelines are warranted.
82 quantitative mp-mri and pathology of recurrent pca after rt
555
5.1 introduction
Depending on the risk group, 5-year disease free survival varies from 67 – 80%
for prostate cancer patients who are treated with whole-gland radiation ther-
apy (RT) to 78 Gy [58]. Most patients with recurrent disease have developed
metastasis, yet a small but significant proportion will harbour locally recurrent
disease only [26, 27]. For these patients, salvage treatment options include
radical prostatectomy, brachytherapy, cryotherapy or high-intensity focused ul-
trasound [33]. Whole-gland approaches, such as salvage radical prostatectomy
(SRP), are reported to obtain good disease control, however with a high chance
of severe gastrointestinal and genitourinary complications when compared with
radical prostatectomy in primary disease [136].
Focal salvage strategies aim at reducing these comorbidities by sparing the
uninvolved tissue while specifically targeting recurrent cancer. When evaluated
in radio-recurrent PCa, the complications of focal approaches are comparable
or lower than in whole-gland strategies, with a 5-year biochemical disease-free
survival of 46.5 – 54.5% [33].
Successful development of focal salvage strategies for local recurrent PCa
requires an accurate detection and localisation of the tumour. Positron emission
tomography (PET) with 68Ga PSMA-ligands, offers high sensitivity to detect
recurrent PCa [13], yet the poor spatial resolution limits its use for focal salvage
strategies. Magnetic resonance imaging (MRI) is alongside PET the most used
modality for recurrence diagnosis. High-resolution anatomical and functional
imaging make MRI attractive for the preparation of focal salvage treatments
[52].
Post-RT benign confounders pose a challenge to MRI interpretation. Prostate
tissue shows diffuse signal intensity (SI) reduction on T2-weighted (T2w) MRI,
complicating tumour detection [37]. The use of 1.5T MR spectroscopy [45] as
well as DWI- and DCE-MRI [40] have been found to surpass T2w in detecting
local recurrence. Thus multi-parametric MRI (mp-MRI) with diffusion-weighted
imaging (DWI) and dynamic contrast enhanced (DCE) MRI is often preferred.
Zattoni et al. [51] reported 3T mp-MRI to have good accuracy in detecting
recurrent disease extension. Conversely, Donati et al. [46] found no additional
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benefit of DCE when added to T2w and DWI. These studies used either biopsy
or SRP samples for validation, but none attempted accurate registration of
imaging and histopathology. To date, no guidelines exist on how to score or
delineate recurrent tumour suspected regions.
In this study 3T mp-MRI is used to characterise irradiated prostate tissue,
using SRP specimens registered to mp-MRI as ground truth. Using high resol-
ution tumour delineations in histopathology, we describe radio-recurrent PCa
and use mixed modelling to establish which imaging sequences result in an op-
timal distinction between tumour and benign voxels. We further investigate the
accuracy of tumour detection in mp-MRI, a crucial element for the development
of focal salvage strategies.
5.2 materials and methods
5.2.1 Patients
Twenty one patients with radio-recurrent PCa, who underwent mp-MRI for local
staging prior to SRP between 2011 and 2017, were retrospectively included.
Biochemical recurrence was established according to the Phoenix criteria [65].
All patients had biopsy-proved recurrence and absence of distant metastasis
on Choline PET scans. External-beam radiotherapy (EBRT) and low-dose rate
(LDR) brachytherapy treated patients were included.
5.2.2 MRI acquisition
Patients were scanned on a 3T Achieva (16), Achieva dStream (3) or Ingenia
(2) MRI scanner (Philips Healthcare) between June 2011 and March 2017.
Thirteen patients were scanned using an endorectal coil in addition to a torso
or cardiac phased array coil. The mp-MRI protocol included triplanar T2w
turbo spin-echo (TE 90-130 ms, TR > 2600 ms) and axial T1-weighted (T1w)
gradient echo (TE < 2.3 ms, TR < 5.3 ms) sequences. DWI was acquired using
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a single-shot spin-echo echo-planar imaging sequence (b-values between 100
and 1000 s/mm2), from which apparent diffusion coefficient (ADC) maps were
generated. DCE was acquired with a 3D T1w spoiled gradient echo sequence
(TE/TR = 2/4 ms), dynamic interval 2.3-2.9 seconds over 5-6 minutes, with
intravenous administration of 7.5 mmol gadoteric acid (Dotarem). For seven
patients the DCE sequence was not acquired. The pharmacokinetic parameter
maps Ktrans and kep were derived from the DCE scans. A balanced Steady-
State Free Precession (bSSFP) sequence was acquired for fiducial and seed
visualization in seven patients. MRI acquisition and post-processing details
can be found in the Supplementary Materials.
Visual inspection was used to assess displacements between the functional
sequences and the T2w scans, with rigid registration performed when necessary.
The T2w voxel size in plane resolution was between 0.3-0.8 mm, with a slice
thickness of 3 mm. All maps were resampled to the T2w grid.
5.2.3 Pathology
Whole-mount axial slides, stained with hematoxylin and eosin (H&E), were used
for histopathological validation. Slides at the apex and base of the specimen
were sliced parasagitally for extra-prostatic extension evaluation and were ex-
cluded from analysis. The slides were digitalised using an Aperio ScanScope
XT (Aperio Technologies). Supervised by an uro-pathologist (6 years of experi-
ence), tumour delineations were made (resolution 0.5 µm/pixel) on the digitised
slides using ImageScope.
5.2.4 T2w-MRI and H&E registration
The registration between H&E slides and the transversal T2w MRI was per-
formed by two observers in consensus. A T2w slice was visually assigned to
each H&E slide. Slide matching was performed considering the order of the
slides, the location of the apex and base of the prostate, visible anatomical
landmarks, and the relative size and shape of subsequent H&E and T2w slices.
Each H&E slide was then registered to its matched T2w slice using deformable
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registration based on landmark points (Coherent Point Drift) [137] implemented
in MATLAB R2015a (The MathWorks). Landmark points included the urethra,
nodules, the prostate boundary, and the tumour.
The registration error was estimated by selecting one landmark per patho-
logy slide and measuring the Euclidean distance between the point in the T2w
and in the registered pathology.
After registration, tumour delineations on the H&E slides were propagated
to MRI. To ensure that only tumour voxels were used to characterise imaging
and train the mixed model, tumour delineations were eroded in all directions
by 1 mm.
All further analyses were restricted to the MRI slices for which a matching
H&E slide existed.
5.2.5 Region of interest segmentation
A ROI was delineated in the levator ani muscle and the median SI in this region
was used to normalise the T2w images. For MRI slices with H&E match the
entire prostate and peripheral zone (PZ) were delineated using the transversal
T2w MRI. The central gland (CG) was defined as the remaining non-PZ region,
comprising the central and transition zone. The peri-urethral (PU) region was
delineated with both sagittal and transversal T2w MRI. All voxels within these
regions were included in the analysis. The location of implanted seeds and
fiducial markers, as visible in the T1w or bSSFP sequences, was removed from
the analyses.
Two uro-radiologists (14 and 7 years of experience) independently delin-
eated suspected tumour regions, having access to mp-MRI and the radiological
report, the PET Choline scans and the biopsy results. Since PI-RADS v2 [42]
is not applicable to recurrent prostate cancer, tumour was defined as a region
with low signal-intensity (SI) on T2w-MRI, high SI in the b = 800 DWI scan,
low SI on the ADC map, and increased enhancement in the Ktrans and kep maps.
Tumour regions delineated on mp-MRI were compared with the delineations
propagated from histopathology, and the distance and overlap were described.
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When overlapping, the distance and spatial overlap were quantified using the
95% Hausdorff distance between contours and the Dice coefficient. Delineated
and pathological volumes were estimated using the T2w grid.
For LDR brachytherapy patients with seminal vesicle (SV) invasion, the
visible tumour areas as well as a benign region were delineated but no distances
with histopathology contours were determined.
5.2.6 Statistics
Significant differences (p < 0.05) of median imaging values between ROIs were
tested with a non-parametric Friedman’s ANOVA. To further examine differences
a post-hoc Wilcoxon signed rank test was used with a Bonferroni correction.
Using the EBRT patients, univariate and multivariate generalised linear
mixed-effect modelling was applied to assess the predictive value of imaging on
the voxel-wise likelihood of tumour. Voxels were grouped as: benign, resulting
from a combination of unaffected PZ and CG for which H&E was available; and
tumour, based on pathology delineations. To obtain the likelihood of tumour on
a voxel level, fixed and random effects were included.
The T2w, ADC, Ktrans, kep maps and voxel anatomical location (PZ or CG)
were included as fixed effects. Random effects accounted for spatial clustering,
by incorporating the voxel relative distance from the prostate centre of mass
and patient identifiers. When the association between model parameters and
tumour probability was nonlinear, the parameters were grouped in quartiles
and regression coefficients were estimated for each group considering the first
quartile as reference. The model fit was assessed using the Bayesian Inform-
ation Criterion (BIC) (a decrease of 10 points reflects an improved fit) and by
evaluating the residual random error. The contribution of predictors such as
time since RT, use of hormonal therapy (HT) and treatment modality, included
as fixed effects, was also investigated. A calibration curve was used to assess
the quality of the best model. Analyses were performed in R (RStudio) using
the lme4 package.
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5.3 results
Thirteen patients had been primarily treated with EBRT and eight with LDR
brachytherapy between 1999 and 2013. Median time between treatment and
the MRI for recurrence diagnosis was 84 months for EBRT and 60 months for
LDR brachytherapy. Following the D’Amico definition [64], 1, 8 and 12 patients
had low, intermediate and high-risk primary PCa. Eleven patients received
HT as part of their primary treatment, but none received HT at the time of
imaging. Patient characteristics can be found in Table 5.1. Gleason score
was not assigned to the recurrent tumour as radiation-induced atypia can be a
confounder for pathological interpretation [138].
5.3.1 Pathological findings
EBRT patients had an average tumour volume of 1.2 cm3, LDR patients 0.51
cm3. For all patients except one, recurrent tumour after LDR brachytherapy
extended to the SV. In this subset, tumour within the gland was mainly small
and sparse. For 2 patients no tumour was visible in the available H&E slides,
with their pathology reports describing tumours of small dimensions in the
prostate apex, bladder neck and/or extension to the SV. These patients were
excluded from further analysis.
The average registration error for all slides was 1.1 ± 0.9 mm. Quantitative
image analysis based on the matched H&E slides was performed for 19 patients
and 56 slides - Figure 5.1. Multifocal recurrent disease was present for all
but one patient. Sixty-three percent of the tumours were located in the PZ and
11% in the CG. The remaining 26% covered both PZ and CG. Benign prostatic
hyperplasia (BPH) could not be seen in the pathology slides matched to MRI.
The pre-SRP biopsy report contained information about the location of positive
cores for 17/21 patients. When compared to the SRP histopathology, biopsy
correctly detected 42% of SV-located tumours, as well as 33% of left and 75%
of right prostate gland tumours.
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Table 5.1: Patient characteristics.
IQR – Interquartile range
Nadir PSA (ng/ml) [IQR] 0.7 [0.9]
Median PSA level at MR imaging (ng/ml) [IQR] 5.4 [3.4]
Median time from MRI to SRP (months) [IQR] 3 [3]
Median iPSA level (ng/ml) [IQR] 15 [22]












Gleason 8 (5+3) 1
Gleason 9 (5+4) 1








Figure 5.1: Example of an EBRT patient. The arrow points at the urethra, location used for
the match of the H&E slide (B) with T2w MRI (A). The registered H&E slide (C)
is placed side by side with the mp-MRI images where the prostate is delineated in
white and the tumour in blue.
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5.3.2 Radiologists’ delineations compared to histopathology
Median delineated volumes (cm3) were 0.34 (range, 0.04–2.14) for radiologist
1 and 0.56 (range, 0.06–3.50) for radiologist 2, and missed tumour foci were
smaller than 1 and 0.5 cm3, respectively.
Radiologists’ contours did not visually overlap with pathology for 5 patients,
with 3 of them missed by both. When overlapping with pathology, the median
delineated volumes (cm3) - 0.61 (range: 0.05-1.76) and 0.68 (range: 0.06-
2.82) – slightly underestimated the corresponding median pathological tumour
volumes (cm3) - 0.74 (range: 0.01-2.82) and 0.74 (range: 0.02-2.82) – Figure
5.2A-C. Contours overlapping with pathology had a median Dice coefficient of
0.64 (range: 0.1–0.8) and 0.58 (range: 0.01-0.83), and a median 95% Hausdorff
distance (mm) of 3.6 (range: 0.4-20.9) and 6.2 (range: 0.9-17.1) for radiologist
1 and 2 respectively.
The pattern of recurrence after LDR brachytherapy, showing small and
sparse foci (Figure 5.2D), together with the artefacts caused by the seeds, made
detection of recurrent tumour within the gland challenging. Disease extension
to the SV was more readily visible as it presented characteristic tumour features
on MRI.
5.3.3 MR Imaging parameters
Diffuse SI reduction throughout the prostate and a decreased conspicuity of
zonal anatomy was observed on T2w. For most patients (10/17 with DCE), the
PU region showed Ktrans enhancement without signs of malignancy – Figure 5.1.
Quantitative imaging values are reported for all ROIs in Figure 5.3 for EBRT
and Figure S5.1 (Supplementary Materials) for LDR brachytherapy patients.
Further information about the values per ROI can be found in Table S5.1
(Supplementary Materials).
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Figure 5.2: Example patients treated with primarily EBRT (A, B and C) and LDR brachyther-
apy (D) with histopathology delineations propagated to MRI (in blue) and tumour-
suspected regions delineated by the experienced uro-radiologists (in yellow and
red).
EBRT patients
The Friedman’s ANOVA test revealed significant differences between regions. A
Wilcoxon signed rank test between tumour and PZ, with a corrected α = 0.05/6
= 0.008, found median ADC (PZ = 1.3 ×10−3 mm2/s, Tumour = 0.9×10−3
mm2/s), Ktrans (PZ = 0.13 min−1, Tumour = 0.23 min−1) and kep (PZ = 0.32
min−1, Tumour = 0.45 min−1) to be significantly different. No imaging modality
was significantly different between tumour and the CG. The PU region had the
highest values for all but kep, with Ktrans (PU = 0.35 min−1) and ADC (PU =
1.4×10−3 mm2/s) significantly higher than tumour. For T2w and Ktrans there
was a considerable overlap between tumour and CG values – Figure 5.3. The
tumour had the lowest T2w and ADC and the highest kep values.
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555Figure 5.3: Median imaging values for all ROIs of the 13 EBRT patients. The boxes represent
the first (25th) and third (75th) quartile; the horizontal line indicates the median
and the whiskers the limit Q1 − 1.5 × Q1 and Q3 + 1.5 × Q3; dots represent
outliers. The asterisk denotes significant differences (p < 0.008).
LDR brachytherapy patients
For LDR brachytherapy patients, no significant differences were found between
ROIs for all imaging modalities – Figure S5.1 (Supplementary Materials). The
majority of the foci in the gland were small and did not have typical tumour
characteristics on mp-MRI. The DWI was degraded due to the presence of the
seeds– Figure 5.4. Similarly to EBRT patients, the PU had the highest values
for all but kep maps. For the seven patients with SV invasion – Table 5.2 -
tumour in the SV had the highest values for Ktrans and kep and lowest ADC and
T2w values.
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Figure 5.4: Example of a LDR-brachytherapy patient in which the DWI sequence is distorted
by the presence of the seeds. The region masked out of the analysis due to the
presence of the seeds (in dark blue) was delineated using the T1w gradient echo
sequence.
Table 5.2: Median imaging values for tumour and benign ROIs in the seminal vesicles for the
LDR-brachytherapy patients presented as median (Q10 – Q90).
Seminal Vesicles
Imaging Parameter Tumour Benign
T2w
Normalised T2 values (SI)
Median 2.9 (2.4 - 4.1) 6.6 (4.2 – 8.4)
DWI
ADC (×10−3 mm2/s)
Median 1.0 (0.9 – 1.9) 1.7 (1.3 – 3.2)
DCE
Ktrans (min−1)
Median 0.20 (0.17 – 0.33) 0.13 (0.06 – 0.22)
kep (min−1)
Median 0.59 (0.48 – 0.79) 0.47 (0.29 – 0.55)
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5.3.4 Mixed-modelling
Univariately, all MRI parameters were significantly associated with tumour like-
lihood, kep having the best statistical performance (BIC of 239552, compared
to 286265, 247260 and 254273 for T2, ADC and Ktrans). Location (PZ = 0
or CG = 1) was the only non-imaging parameter that improved discrimination,
with a voxel location in the CG decreasing tumour likelihood. A multivariate
model combining all mp-MRI parameters and location obtained the best fit and
was the most predictive for tumour (BIC of 198942, p < 0.001) – Table S5.2
(Supplementary Materials). A calibration curve for this model can be found
in the Supplementary Materials (Figure S5.2), showing that model predicted
probabilities correspond well to the actual fractions of voxels with tumour in
histopathology. Figure 5.5 shows an example of a reconstructed tumour prob-
ability map originating from the use of the mp-MRI model.
Figure 5.5: (A) Tumour likelihood (with probabilities between 0 and 1) for every prostate
voxel, obtained with the use of the multivariate mp-MRI model. (B) Region with
probability values above 0.5 (red overlay on the T2w). (C) True pathological extent
based on the matched H&E slide (yellow overlay on the T2w).
5.4 discussion
In selected patients, focal salvage can achieve local control while reducing the
risk of adverse events. An accurate representation of tumour location is neces-
sary and mp-MRI has been used for this purpose [139–142]. In a quadrant ana-
lysis, T2w alone was reported to result in a similar tumour evaluation accuracy
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as in the pre-treatment setting, but with substantial interobserver variability
[56]. Benign confounders in previously irradiated prostates can complicate tu-
mour detection. No consensus exists yet on the optimal MRI sequences for
detecting local recurrence. Since patients only sporadically receive SRP after
RT, and with limited availability of mp-MRI prior to surgery, studies reporting
on these patients are usually based on small numbers [45, 55, 56]. Our study
is unique in registering pathology to MRI to propagate high resolution tumour
delineations.
Consistent with literature, we found radio-recurrence disease to be often
multifocal [57] yet with a different recurrence pattern in EBRT and LDR bra-
chytherapy treated patients. No BPH was found in the available pathological
slides, suggesting that it is not an imaging confounder as in the untreated
prostate.
Our findings have implications for the design of focal salvage treatments.
Smaller foci were often missed, and when overlapping with pathology, radiolo-
gists’ delineations often underestimated the real tumour size. Both radiologists
performed quite similarly regarding the evaluated metrics. Our results are in
line with findings in the de-novo setting, comparing mp-MRI tumour detection
to prostatectomy specimens: Borofsky et al. [143] reported that in 26% of the
patients clinically important lesions were missed and in 8% there was substan-
tial tumour size underestimation; according to Bratan et al. [144] two observers
underestimated tumour volume with every pulse sequence and Steenbergen et
al. [49] described how teams of observers missed all small satellites and parts
of the 18/22 correctly detected dominant lesions. In the setting of recurrent
PCa, tumour volume underestimation in 1.5T T2w MRI has been described us-
ing SRP samples [55]. The 95% Hausdorff distances here reported were above
the 2.3mm error observed in primary tumour delineations on mp-MRI [49]. Our
results suggest a margin could improve index lesion coverage in focal salvage
strategies. The development of MRI scoring and recurrent tumour delineation
guidelines would likely improve consistency between observers and studies.
Analysis of the quantitative imaging maps showed that for EBRT patients
Ktrans, kep and ADC could successfully distinguish tumour in the PZ. Tumour
detection in the CG was hampered by the presence of PU enhancement of Ktrans.
Recurrent PCa after LDR brachytherapy was challenging to image due to the
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seeds, causing severe distortions in the DWI, and potentially unreliable ADC
values. For these patients, no significant differences were found between ROIs,
possibly due to the small sample size.
Using mixed-modelling, the mp-MRI combination obtained the best perfor-
mance in distinguishing tumour and benign tissue on a voxel-level. Location
significantly contributed to tumour likelihood, mimicking primary tumour preval-
ence maps in which the PZ has higher tumour incidence. The addition of DCE
parameters improved tumour distinction. The decreased accuracy reported by
Donati et al. [46] may have been caused by the PU enhancement confounder.
The limited prostate coverage by the H&E slides made it impossible to re-
construct the overall shape of the gland, limiting registration accuracy between
the slides and MRI. The main study limitation is the small sample size.
In conclusion, when using MRI to guide focal salvage treatments, all ima-
ging modalities should be used for delineation, and the recommended treatment
plan should encompass adequate margins beyond the visible tumour to accom-
modate for size underestimation. Tumour multifocality should also be accounted
for. De-escalated whole gland treatment with a focal tumour boost could po-





5.5.1 MRI acquisition and post-processing
The T2w scans were acquired with an echo time (TE) between 90 – 130 ms, and
a repetition time (TR) between 2600 – 6000 ms. The T1w gradient echo scans
were acquired with a TE between 1.8 – 2.3 ms and a TR between 3.6 - 5.3 ms.
For one patient the T1w sequence was a turbo spin-echo with TE/TR = 8/572
ms. The DCE sequence was acquired with a TE/TR = 2/4 ms. Contrast injection
was followed by a 30 ml saline flush at a flow rate of 3 ml/s. The apparent
diffusion coefficient (ADC) maps were derived from the DWI data excluding b-
value = 0. In 12 patients the b-values (s/mm2) = 200 and 800 were used; for 2
the used values were b (s/mm2) = 500 and 1000 and in 1 patient the values of b
(s/mm2) = 100 and 1000. For 6 patients, up to 4 b-values between 100 – 800
were used. Pharmacokinetic analysis was performed with the standard Tofts
model [145], using an average T1 value of 1597 ms [146] and an arterial input
function with parameters derived from an in-house study population. DCE and
DWI- derived maps were generated using MATLAB R2015a (The MathWorks).
Further region of interest (ROI) analysis was performed using Python 3 (Python
Software Foundation).
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Figure S5.1: Median imaging values for all ROIs of the six LDR brachytherapy patients. The
boxes represent the first (25th) and third (75th) quartile; the horizontal line indic-
ates the median and the whiskers the limit Q1 − 1.5 × Q1 and Q3 + 1.5 × Q3;
dots represent outliers.
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Figure S5.2: Relation between the fraction of voxels with tumour as observed in histopath-
ology and the probability of tumour as obtained from the model. For voxels
within a probability interval of 0.05, the fraction of voxels identified as tumour
in the histopathology was calculated. For each interval, this fraction was plotted
against the averaged predicted probability by the model. The dashed line repres-
ents perfect correspondence between observed fraction and predicted probabil-
ity.
Table S5.1: Median values for both subsets of patients and all ROIs. Median (Q10 – Q90).
EBRT
Tumour PZ CG PU
T2w (normalised SI) 2.6 (2.3 - 3.3) 3.5 (2.3 - 4.2) 2.8 (2.0 - 3.7) 3.3 (2.3 - 4.9)
ADC (×10−3 mm2/s) 0.9 (0.7 - 1.4) 1.3 (0.9 - 1.7) 1.3 (0.9 - 1.5) 1.4 (1.0 - 1.7)
Ktrans (min−1) 0.23 (0.15 - 0.33) 0.13 (0.07 - 0.17) 0.23 (0.14 - 0.31) 0.35 (0.23 - 0.45)
kep (min−1) 0.45 (0.37 - 0.61) 0.32 (0.24 - 0.37) 0.35 (0.27 - 0.44) 0.43 (0.32 - 0.52)
LDR brachytherapy
Tumour PZ CG PU
T2w (normalised SI) 3.2 (2.4 - 3.7) 3.9 (2.3 - 4.2) 3.0 (2.1 - 3.9) 3.9 (3.1 - 5.0)
ADC (×10−3 mm2/s) 1.3 (1.1 - 1.7) 1.5 (1.3 - 2.3) 1.5 (1.2 - 2.3) 1.7 (1.3 - 2.8)
Ktrans (min−1) 0.18 (0.13 - 0.49) 0.12 (0.10 - 0.25) 0.19 (0.15 - 0.27) 0.35 (0.33 - 0.64)
kep (min−1) 0.44 (0.37 - 0.76) 0.32 (0.31 - 0.37) 0.36 (0.34 - 0.37) 0.50 (0.45 - 0.56)
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Table S5.2: Model parameters obtained when combining T2w, ADC, Ktrans and kep imaging
values to predict tumour at the voxel-wise level. Imaging values and location are
included as fixed effects; patient and spatial coordinates as random effects.
Fixed effects (MRI) Regression coefficients (β) Std. Error P
T2w -0.29 0.01 <0.001
ADC reference group (0 – 0.924×10−3) 0 – –
ADC 2nd quartile (0.925×10−3 – 1.222×10−3) -1.70 0.02 < 0.001
ADC 3rd quartile (1.223×10−3 – 1.438×10−3) -2.58 0.02 < 0.001
ADC 4th quartile (1.439×10−3 – 3.825×10−3) -3.35 0.03 < 0.001
Ktrans reference group (0 – 0.120) 0 – –
Ktrans 2nd quartile (0.121– 0.160) 0.30 0.02 0.594
Ktrans 3rd quartile (0.161 – 0.248) 1.70 0.02 <0.001
Ktrans 4th quartile (0.249 – 2.494) 2.26 0.03 <0.001
kep 4.95 0.05 <0.001
Location -1.44 0.02 <0.001
Intercept (β0) -2.35 0.41 <0.001
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abstract
Purpose: Focal salvage treatments of recurrent prostate cancer (PCa) after ra-
diation therapy require accurate delineation of the target volume. Magnetic
resonance imaging (MRI) is used for this purpose; however radiation therapy-
induced changes complicate image interpretation, and guidelines are lacking
on the assessment and delineation of recurrent PCa. A tumour probability (TP)
model was trained and independently tested using multi-parametric MRI (mp-
MRI) of patients with radio-recurrent PCa. The resulting probability maps were
used to derive target regions for radiotherapy treatment planning.
Methods and Materials: Two cohorts of patients with radio-recurrent PCa were
used in this study. All patients underwent mp-MRI (T2 weighted, diffusion-
weighted imaging, and dynamic contrast-enhanced). A logistic regression model
was trained using imaging features from 21 patients with biopsy-proven recur-
rence who qualified for salvage treatment. The test cohort consisted of 17
patients treated with salvage prostatectomy. The model was tested against
histopathology-derived tumour delineations. The voxel-wise TP maps were
clustered using k-means to generate a gross tumour volume (GTV) contour for a
voxel-level comparisons with manual tumour delineations performed by 2 radi-
ologists and with histopathology validated contours. Later, k-means was used
with 3 clusters to define a clinical target volume (CTV), high-risk CTV and GTV,
with increasing tumour risk.
Results: In the test cohort, the model obtained a median (range) area under the
curve of 0.77 (0.41–0.99) for the whole prostate. The GTV delineation resulted
in a median sensitivity of 0.31 (0–0.87) and specificity of 0.97 (0.84–1.0) with
no significant differences between model and manual delineations. The 3-level
clustering GTV and high-risk CTV delineations had median sensitivities of 0.17
(0-0.59) and 0.49 (0-0.97) and specificities of 0.98 (0.84-1.00) and 0.94 (0.84-
0.99), respectively.
Conclusions: The TP model obtained a good performance in predicting voxel-
wise presence of recurrent tumour. Model-derived tumour risk-levels achieved
sensitivity and specificity similar to manual delineations in localising recurrent
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tumour. Voxel-wise TP derived from mp-MRI can in this way be incorporated
for target definition in focal salvage of radio-recurrent PCa.
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6.1 introduction
Radiation therapy is an important treatment modality for primary prostate can-
cer (PCa). The 5-year disease-free survival of patients with PCa treated with
external-beam radiation therapy (EBRT) to 78 Gy varies from 67 to 80% de-
pending on the risk group [58]. Although most of the patients with recurrent
disease will bear metastases, a significant proportion will harbour locally re-
current disease only [26]. Because of the toxicity rates associated with whole-
gland salvage treatments, and given the pathological evidence that recurrence
occurs predominantly at the site of the primary index lesion [55], focal salvage
strategies are emerging for locally recurrent PCa without metastatic spread.
This could limit toxicity. The extent of ablation varies from focal with a spe-
cified margin around the lesion, to hemi or zonal [147]. A variety of techniques,
such as cryotherapy [148], HIFU [139], Iodine-125 (low dose rate [LDR]) [53]
and high dose-rate brachytherapy [54] obtained control rates in-line with bio-
chemical disease-free survival outcomes from whole-gland approaches.
Accurate detection and delineation of tumours is important for the design
of focal treatments. Positron emission tomography (PET) with 68Ga prostate-
specific membrane antigen (PSMA) ligands is used to identify metastatic dis-
ease and offers a high sensitivity to detect recurrent PCa [13]. Studies of fo-
cal salvage treatments frequently use multi-parametric MRI (mp-MRI) together
with biopsy confirmation to define the region to treat [33]. High-resolution ana-
tomical and functional imaging makes MRI attractive for guiding focal salvage
treatments. In the setting of recurrent PCa after radiation therapy, benign MRI
confounders are present and can complicate image interpretation and tumour
detection [37]. The Prostate Imaging Reporting and Data System (PI-RADS)
version 2 guidelines do not apply in the recurrent setting [42], and to date, no
consensus guidelines exist on how to delineate recurrent PCa.
Automated methods could aid radiation oncologists in delineating the recur-
rent tumour. As an alternative to manual contouring, automated methods were
developed for primary PCa in which voxel-wise tumour probability (TP) maps,
representing the probability of tumour presence in each voxel, were derived
from MR imaging information [62, 149–152].
108 tumour probability model for locally recurrent pca after rt
666
The purpose of this study was to train and test a TP model for the detection
and delineation of recurrent PCa. We used the model structure described by
Dinh et al. [149], which we trained and validated on 2 independent cohorts of
patients with recurrent PCa after radiation therapy. The performance of the
model in detecting and delineating recurrent PCa was compared to histopath-
ology and with manual tumour delineations.
6.2 methods and materials
6.2.1 Patients
Two independent cohorts were used in this study. The training cohort con-
sisted of 21 patients with biopsy-proven recurrent PCa after EBRT treatment
for primary PCa who qualified for salvage treatment. All patients were imaged
more than 24 months after completion of EBRT and none received hormonal
therapy (HT) in the year before imaging. This was a subgroup of a prospect-
ively collected cohort [153] that had given informed consent prior to particip-
ation in the study. The test cohort consisted of retrospectively collected data
from 17 patients treated with salvage radical prostatectomy for recurrent PCa
after radiotherapy [127]. Written informed consent was waived by the institu-
tional review board. None of the patients received HT at the time of imaging.
All training and test patients received mp-MRI for the diagnosis of recurrent
disease.
6.2.2 Image acquisition
The training cohort patients were scanned on a 3T Achieva dStream (n=3) or
Ingenia (n=18) MRI scanner (Philips Healthcare) between September 2016
and June 2018. With the exception of 4 patients (3 scanned in the Achieva
dStream), all were scanned with the use of an endorectal coil. The test co-
hort patients were scanned on a 3T Achieva (n=12), Achieva dStream (n=3)
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Table 6.1: Sequence specific parameters for the two cohorts.
Training cohort Test cohort
tT2w
Sequence turbo spin-echo
Pixel size/slice thickness (mm) 0.27/3.0 0.3- 0.8/3.0
TR/TE (ms) 3143/120 2600-6000/90-130
DWI
Sequence single-shot spin-echo echo-planar
Pixel size/slice thickness (mm) 1.03/2.7 2.73/4.0
TR/TE (ms) 3131/55 7110–9900/67
b-Values (s/mm2) 0, 200, 800 0, 100 - 2000
DCE
Sequence 3D T1w spoiled gradient echo sequence
Pixel size/slice thickness (mm) 1.16/6.0 1.37–1.68/4.0
TR/TE (ms) 4/1.9 2/4
Dynamic scan time (s) 2.6 2.3-2.5
or Ingenia (n=2) MRI scanner between June 2011 and March 2017. Eleven
patients were scanned with an endorectal coil in addition to a torso or car-
diac phased array coil. In both cohorts, the mp-MRI protocol consisted of
transverse, coronal and sagittal T2-weighted (T2w) turbo spin-echo, axial T1-
weighted (T1w) gradient echo, diffusion-weighted imaging (DWI), and dynamic
contrast enhanced (DCE) MRI. Table 6.1 describes sequence specific paramet-
ers. Apparent diffusion coefficient (ADC) maps were derived from the DWI data
using a mono-exponential fit, excluding b-value = 0. In the training cohort the
ADC map was calculated using the values b = 200 and 800 s/mm2, whereas in
the test cohort the values used varied on a patient level between 100 – 1000
s/mm2. The pharmacokinetic maps Ktrans and kep were derived from the DCE
scans with the Tofts model using a population-based arterial input function
[145, 154].
To minimise the impact of different acquisition protocols, the T2w, Ktrans,
and kep values were normalised to the median value in the peripheral-zone.
The T2w scans do not provide quantitative information and, although Ktrans and
kep are in theory quantitative, the repeatability of the exams is challenging.
Normalisation was not necessary for the ADC maps.
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6.2.3 Ground-truth tumour delineations
The ground-truth tumour delineations in the training cohort were defined on
mp-MRI based on the radiologic report, biopsy and PSMA-PET findings [153].
In the test cohort, the ground-truth tumour delineations were made on the digit-
alised hematoxylin and eorsin (H&E) slides at a resolution of 0.5 µm/pixel. The
first step of the registration between H&E slides and the transversal T2w MRI
was performed visually, assigning a T2w slice to each H&E slide. Each H&E
slide was then registered to its matched T2w slice using deformable registration
based on landmark points (Coherent Point Drift) [137] implemented in MATLAB
R2015a (The MathWorks). The ground-truth tumour delineations were defined
based on the annotated pathology slides and tumour contours propagated to
MRI [127]. All images were registered to the T2w scan, and all maps were
resampled to the grid of the T2w scans in the training cohort (voxel size = 0.27
x 0.27 x 3mm3). Per patient, the dataset consisted of ADC, normalised T2w,
Ktrans and kep images, plus tumour and prostate delineations.
6.2.4 Tumour probability model
In total, 31 intensity and textural-based image features were extracted from the
transversal T2w, ADC, Ktrans and kep as described in [149]. For each voxel, the
intensity values of the ADC and normalised T2w, Ktrans and kep were included.
From the T2w images, the extracted textural features consisted of Gaussian
derivatives up to second order at 4 exponentially increasing scales (σ = 1.5,
2.4, 3.8, 6 mm), summing up to 6 features per scale. Normalised multiscale
blobness textural features were extracted from the ADC, Ktrans, and kep images
over the same 4 scales, resulting in 1 feature per image. It is known that the use
of HT causes a homogenisation of the signal across the prostate. To investigate
if the use of HT had an effect on the normalised T2w signal intensity (SI), the
features from patients with and without previous HT treatment were compared
in both the training and test set.
As described in the same publication, a logistic regression model was fit-
ted to the data to derive a per-voxel TP for the presence of tumour. This same
methodology was used in the current study to derive TP maps for the presence
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of recurrent PCa. Prior knowledge, such as biopsy or prevalence maps, was
not used. Time since radiation therapy was also not included because in previ-
ous research this parameter did not significantly improve voxel-wise recurrent
tumour discrimination [127].
The importance of every feature was assessed by ranking it in the training
set using the Mahalanobis distance [155] between the 2 classes (benign vs
tumour) as a ranking criterion. The model coefficients were retrieved. MATLAB
R2015a (The MathWorks) was used for feature extraction and to develop the
tumour probability model.
6.2.5 From probabilities to risk-levels
The model output was a voxel-wise TP map, permitting the use of a binary
threshold to define the tumour region (gross tumour volume [GTV]). However,
instead of defining a binary threshold for tumour presence, all voxel-wise prob-
ability information can be incorporated [122]. A more moderate solution is to
stratify the probability maps in 3 levels of low-, intermediate- and high-risk for
the presence of tumour. To make the connection with radiation therapy and to
define understandable treating volumes, the 3 risk categories can be labeled
clinical target volume (CTV), high-risk CTV and GTV [156, 157]. In this study
we analysed both approaches by applying a k-means clustering algorithm to
partition the data. The k-means algorithm was used with 2 clusters to define
a binary GTV delineation and surrounding CTV, and with 3 clusters to identify
the CTV, high-risk CTV and GTV. The squared arithmetic distance was the met-
ric used for minimisation. The clustering procedure was repeated 3 times with
new randomly selected initial cluster centroid positions, and the solution with
the lowest within-cluster sums of point-to-centroid distances was selected. The
3 clusters were sorted in ascending order according to their mean TP values,
defining the CTV, high-risk CTV and GTV.
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6.2.6 Comparison between manual- and model-derived tumour delineations
On the test cohort, manual delineations of tumour suspected regions were in-
dependently performed by 2 uro-radiologists (14 and 7 years of experience)
based on the mp-MRI and radiologic report, choline PET scans, and biopsy
information [127]. Because PI-RADS v2 [42] is not applicable to recurrent PCa,
tumour was defined as a region with low SI on T2w MRI, high SI on the b =
800 DWI scan or otherwise comparable b-value DWI scan, low SI on the ADC
map, and increased enhancement in the Ktrans and kep maps.
The model-defined binary GTV delineations and the delineations by the
2 radiologists were compared to the histopathology-defined ground-truth tu-
mour delineations. A voxel-wise assessment of true positives and true negat-
ives obtained by each delineated region resulted in per-patient specificity and
sensitivity values.
6.2.7 Statistics
Clinical characteristics of primary and recurrent tumours were compared between
cohorts. For the statistical analysis, and due to the small number of patients
in some of the highest and lowest categories, the TNM stage was grouped in
2 (T1+T2 and T3+T4) and the Gleason score in 3 groups (Gleason score 6
6, 7, and > 8). Continuous variables (prostate-spefific antigen [PSA]) were
compared using a t-test and categorical variables (Gleason score and TNM
stage) with a chi-square test. Significance was set at p < 0.05. In the test
cohort, a Wilcoxon signed rank test was used to compare the sensitivity and
specificity values between radiologists and against model-derived tumour de-
lineations. The significance value was Bonferroni corrected by the number of
tests. When performing comparisons using the binary GTV delineation the num-
ber of tests was 6 with p = 0.0083, while for the 3-level risk n=10, resulting
in a p=0.005. Statistical tests were performed with the Statistical Package for
Social Sciences, version 22.0 (SPSS, Chicago, IL, USA).
The area under the curve (AUC) values were determined on a voxel-by-
voxel basis. For the training cohort, individual AUC values were obtained by
using leave-one-patient-out cross validation. For the test cohort, the model
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was individually tested and an AUC value was obtained per patient. Population
median and ranges are reported.
6.3 results
6.3.1 Patient characteristics
Patient characteristics from both cohorts are reported in Table 6.2 for primary
PCa and Table 6.3 for recurrent disease. The test cohort consisted of both
EBRT (n=13) and LDR brachytherapy-treated (n=4) patients. Characteristics
of primary PCA were not significantly different between cohorts (TNM stage,
p=0.75; Gleason score, p=0.319; PSA, p=0.095; and use of HT, p=0.293).
However, recurrent tumour PSA levels and TNM stage were significantly higher
in the test cohort (TNM stage, p=0.003; PSA, p=0.014). Gleason score was
not assigned to recurrent tumour [138].
Summary statistics for the values of features in both training and test co-
horts can be found in the Table S6.1 in the Supplementary Materials. The
median (5th – 95th percentile) T2w SI in the training cohort was 0.89 (0.49
– 1.35) for patients who had previously received HT and 0.88 (0.49-1.31) for
those without HT. In the test cohort, the median T2w SI was 0.92 (0.49 – 1.46)
for patients who had previously had HT treatment and 0.95 (0.47 – 1.45) for
those without HT.
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Table 6.2: Patient characteristics for primary prostate cancer.
* For one patient in training cohort no information was available about Gleason score or
PSA levels of primary tumour.
Primary PCa













PSA levels (ng/ml) *
<10 8 4
10 6 PSA <20 6 6





Table 6.3: Patient characteristics for recurrent prostate cancer.
† For two patients in the training cohort no information about TNM stage of recurrent
tumour was available.
Recurrent PCa















10 6 PSA <20 1 3
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Table 6.4: Feature ranking. Gi(s) stands for the Gaussian derivative in the direction i, with
standard deviation s (in mm).
Rank Feature name
1 kep - Intensity
2 kep - Blobness
3 Ktrans - Blobness
4 Ktrans - Intensity
5 ADC - Blobness
6 ADC - Intensity
7 T2w – Texture, G(3.8)
8 T2w – Texture, G(6)
9 T2w – Texture, G(2.4)
10 T2w – Texture, Gxx(1.5)
6.3.2 TP model performance
Training cohort
Based on the MRI-based delineations used as ground-truth, the tumour preva-
lence in the training cohort was 6%. The median (range) tumour volume was
0.70 (0.11-4.15) cm3. Table 6.4 lists the top 10 ranked features. The 4 highest
ranking features were perfusion based, with kep ranking first. The model coeffi-
cients can be found in Table S6.2 in the Supplementary Materials.
The TP model achieved a median AUC = 0.94 (range, 0.62-0.99). The
binary GTV delineation obtained a median (range) sensitivity of 0.50 (0.17-
0.90) and specificity of 0.98 (0.89-1.00). The GTV delineation had a median
(range) volume of 0.83 (0.33-3.87) cm3.
Test cohort
Based on the histopathology ground-truth, the tumour prevalence in the test
cohort was 9%. The median (range) histopathology tumour volume was 0.67
(0.07-2.93) cm3.
results 117
The TP model obtained a median AUC = 0.77 (range, 0.41–0.99). The
binary GTV delineation resulted in a median (range) sensitivity of 0.31 (0-0.87)
and specificity of 0.97 (0.84-1.00). An example of the input mp-MRI and the
resulting TP and risk-level maps is illustrated in Figure 6.1 for a patient in the
test cohort. In 1 patient, the tumour was entirely missed by the model-defined
GTV region. Table S6.3 in the Supplementary Materials reports the sensitivity
and specificity values for all individual patients. The model-defined GTV had a
median (range) volume of 0.65 (0.07-2.62) cm3. The calibration (Figure S6.1)
and ROC curves (Figure S6.2) for the training and test cohorts can be found
in the Supplementary Materials. The calibration curve of the test set revealed
that for low probabilities the model underestimated the fraction of tumour voxels
and for high probabilities it overestimated the prevalence of tumour.
The regions defined by the 2 radiologists obtained a median (range) sens-
itivity of 0.33 (0-0.76) and 0.34 (0-0.91) and specificity of 0.99 (0.93-1.00) and
0.99 (0.72-1.00). The sensitivity and specificity values were not significantly
different between the 2 radiologists. In total, the radiologists missed the tumour
in 4 patient, and 2 of these were missed by both experts. One of these tumours
was also missed by the model-defined GTV region. No significant differences
were found between the sensitivity and specificity values of model and manual
delineations. The delineations performed by the 2 radiologists had a median
(range) volume of 0.17 (0-2.22) and 0.44 (0-3.52) cm3.
Three-level risk map
The 3-level risk map defined a CTV, high-risk CTV and GTV. In the training
cohort, the GTV resulted in a median (range) sensitivity of 0.26 (0.06-0.69) and
specificity of 0.99 (0.96-1.00), whereas the region encompassed by the high-
risk CTV resulted in a median sensitivity of 0.71 (0.28-0.98) and specificity of
0.95 (0.78–0.99). The delineated GTV had a median (range) volume of 0.54
(0.09-2.23) cm3, and the high-risk CTV of 1.78 (0.57-7.71) cm3.
In the test cohort, and compared to the histopathology-derived ground-
truth delineations, the GTV resulted in a median (range) sensitivity of 0.17
(0-0.59) and specificity of 0.98 (0.84-1.00), whereas the high-risk CTV delin-
eation obtained a median sensitivity of 0.49 (0.00-0.97) and specificity of 0.94
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Figure 6.1: Example patient from the test cohort with input MR images, tumour probability
map, and defined risk-regions. In the first row, are the the mp-MRI scans with the
prostate delineation in white and the ground-truth tumour delineation in cyan. In
the second row, from left to right, a TP map, the two- and three-level risk maps and
the histopathology section. In the third row, the individual delineations from the
first (yellow) and second (red) radiologists are displayed, as well as an overlap of
both delineations with the ground-truth tumour delineation (bottom right corner).
The fiducial markers were removed from the analysis, explaining the hole in the
tumour probability map.
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Figure 6.2: Visual representation of the results obtained for three patients in the test cohort.
From left to right: the hematoxylin and eosin (H&E) slides, the model-derived two-
and three-level risk maps, and the corresponding radiologist’s delineations for 3
patients in the test cohort. The yellow and red contours represent the delineations
by the 2 radiologists, and the cyan is the ground-truth tumour delineation.
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(0.84-0.99). In 1 patient the tumour was entirely missed by the model-defined
GTV and by the high-risk CTV. The delineated GTV had a median (range)
volume of 0.27 (0.02-2.62) cm3 and the high-risk CTV of 1.20 (0.07-2.67) cm3.
With the exception of the specificity values between the high-risk CTV and the
first radiologist (p<0.001), no significant differences were found between the
sensitivity and specificity of model-derived and manual delineations.
Figure 6.2 illustrates the H&E slides next to the model-derived 2- and
3-level risk maps as well as the corresponding radiologist’s delineations for 3
patients in the test cohort.
6.4 discussion
Accurate detection and localisation of the recurrent tumour is essential for the
design of focal salvage treatments. However, to date no guidelines exist on
how to interpret mp-MRI of recurrent PCa after radiation therapy. To deal
with this lack of radiological guidelines, we propose the use of a TP model with
different risk levels. Radiation therapy using dose painting by numbers, in which
higher doses are given to voxels with a higher TP, is a possible strategy for
focal salvage treatments. Our model fits this idea as it provides a probabilistic
estimate of tumour presence. To translate the model outcome to a practical input
for radiation therapy, the probability values were clustered to define 3 risk levels
for tumour presence: CTV, high-risk CTV and GTV. Although variable treatment
schemes are reported in the literature, brachytherapy offers the possibility to
provide an ultra-conformal treatment while permitting dose escalation. Doses
for LDR brachytherapy range from 120 to 145 Gy for 125I, and 90 to 113 Gy
for 103Pd [158]. The 3-level risk map derived from our MRI-based voxel-wise
TP model could be used to target the different regions with varying doses.
Based on salvage LDR brachytherapy studies [53, 142, 159] the GTV could be
prescribed to a dose of 144 Gy, the high-risk CTV could function as a margin
around the GTV for decreasing treatment dose, while ensuring the CTV would
receive a dose of 108 Gy.
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The TP model developed here was tested on an independent cohort with
accurate histopathology-based ground-truth and obtained an AUC = 0.77 for
the voxel-wise prediction of recurrent tumour presence. According to [160], the
AUC value of our model can be interpreted as good diagnostic accuracy (0.7
< AUC < 0.8). To our knowledge no studies report voxel-wise sensitivity and
specificity values for recurrent PCa detection. Using T2w + DWI + DCE and
biopsy as ground-truth, Luzurier et al. [47] used 2 teams of radiologists to
assign a Likert score to each prostatic sextant for the likelihood of recurrent
tumour after radiotherapy. The AUC varied between 0.898 and 0.946 on a lobe-
level and 0.853 and 0.905 on a sextant-level. Many studies have derived models
for the detection of primary PCa, with reported AUC values ranging from 0.61
to 0.96 [62, 149, 150, 152, 161]. The AUC value obtained by our model is well
within the interval of values reported for primary PCa detection.
In our model, the top ranking features were perfusion based. This suggests
an increased importance of DCE-derived parameters in the recurrent setting
when compared with primary tumour detection. When assessing primary PCa
according to the PI-RADS v2 guidelines, DCE-MRI has a limited role com-
pared to T2w and DWI [42] since the presence of benign prostatic hyperplasia
(BPH) in the central-gland is a major imaging confounder. On the other hand,
identifying recurrent disease with DCE-MRI is easier than primary PCa detec-
tion because of the different enhancing patterns between tumour and benign
tissue [37]. In addition, BPH was not found in the analysed histopathology
of irradiated prostates [127]. Nonetheless, attention should be given to the
increased enhancement around the peri-urethral tissues in Ktrans and kep maps
without evident signs of malignancy [153]. T2w-derived features were found to
be considerably less important than in the pre-treatment setting, potentially as
a result of the overall decrease in T2 values after radiation therapy [37]. The
previous use of HT up to 1 year prior to the MRI examination did not seem to
have an impact on the T2w signal intensity in patients after radiation therapy.
The voxel-level sensitivity and specificity in detecting recurrent tumour was
compared between model-defined binary GTV contours and the delineations by
2 expert uro-radiologists. The sensitivity and specificity of the high-risk CTV
and GTV delineations obtained when clustering the data in 3 risk-levels for
tumour presence were also assessed. All of the methods obtained comparable
and very high specificity and low sensitivity. We observed a wide range of
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sensitivity values for the model in both training and test cohorts, as well as
with radiologist-made delineations. These results suggest that some tumours
are intrinsically hard to detect. As reported by Greer et al. [162] in primary
PCa, the combination of a computer-aided diagnosis (CAD) system with expert
knowledge might result in improved sensitivity also in recurrent PCa. Neverthe-
less, this sensitivity improvement was traded against a decrease in specificity
due to CAD-induced false positives. Because recurrent PCa tends to occur
at the location of the primary tumour [55] another way to improve the model
sensitivity and remove false positives could be to include the pre-treatment MRI
scans or the location of the primary tumour. In addition, the high sensitivity and
specificity of PSMA-PET in detecting recurrent PCa (9) suggests that adding
this imaging modality would improve model performance. To suppress central-
gland confounders, a prevalence map was included in the model by Dinh et al.
[149]. After radiation therapy, confounders such as BPH are expected to have
vanished, and the benefit of including a prevalence map for recurrent PCa de-
tection will likely not outweigh the decrease in sensitivity in the central-gland.
Since the training cohort patients received MRI-transrectal ultrasound fusion
biopsies, the information provided by a biopsy map was not independent from
the MRI; thus these were not included as features.
Despite having similar feature characteristics, the 2 cohorts had different
definitions of ground-truth, as seen in the calibration curve of the test data set,
where for low values of TP the actual fraction of tumour was higher than the
model prediction. This is consistent with a training based on manual delin-
eations, where poorly visible cancers are often missed entirely. For high values
of TP, we noticed that the actual fraction of tumour was lower than predicted.
This is also consistent with a manual delineation that is typically generous
and overestimates the size of a visible lesion. Using a salvage prostatectomy
cohort for training of the model would likely overcome the bias introduced by
manual delineations. However, because of high treatment-related toxicity, sal-
vage prostatectomy is not commonly performed and retrieving such a data set
is practically very difficult. We have chosen to use the available salvage pro-
statectomy cohort to test the model because in this way it was possible to
compare the model results with histopathology ground-truth, resulting in more
solid conclusions about the model performance. Other study limitations include
the relatively small number of patients and that the training and test cohorts
had different recurrent tumour characteristics. Although power calculations for
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binary classifications are possible [163], our problem is not a classification on
a patient level, since all patients have a recurrence. Power calculations on
voxel level would disregard the fact that the many voxels are not necessarily
independent. Our validation in an independent test cohort of patients did show
a decrease in AUC from 0.94 to 0.77. Although this can, to some extent, be
explained by overfitting, it must also be attributed to the use of manual delin-
eations as ground-truth in the training cohort, compared to whole-mount sec-
tion histopathology in the test cohort. In the test cohort, tumour prevalence was
biased because only slices with histopathology validation were used. Lastly,
despite striving for the best possible match between histopathology and ima-
ging, registration errors arising from this process result in some uncertainty in
the exact boundary between tumour and benign tissue. The registration can be
complicated when prostate deformations caused by imaging with an endorectal
coil are present. However, we observed that by using deformable image regis-
tration, the matches between H&E and T2w slices were overall successful. As
reported in the original publication describing this salvage prostatectomy co-
hort [127], the in-plane average registration error was for all slides of 1.1 ± 0.9
mm. In the present study, registration inaccuracies were not taken into account.
This could mean that we might be underestimating the AUC values compared
to when registrations errors are compensated (eg, by accounting neighbouring
voxels). When designing radiation therapy treatments this problem is mitigated
because the limited steepness of the dose fall-off means that a voxel next to a
suspected tumour voxel would still receive a considerable dose.
6.5 conclusion
This study demonstrates that it is feasible to use mp-MRI information to de-
rive target volumes for focal salvage treatments in radio-recurrent PCa. An
independently validated TP model based on mp-MRI obtained sensitivity and
specificity values comparable to those of manually-defined regions in contour-
ing recurrent tumour. Thus, TP maps could potentially be used as an input for
the planning of focal salvage treatments.
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supplementary materials
Figure S6.1: Calibration plots in the train (A) and test (B) cohorts.
Figure S6.2: Receiver operating characteristic (ROC) curves for each individual patient in the
training (A) and test (B) cohorts.
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Table S6.1: For every feature the median value are reported for the training and test cohorts.
In brackets are the 5th and 95th percentiles. With exception of the 95th percentile
of the 31st feature in the test cohort, which is inflated by a single patient with
abnormally high kep blobness values, the values are comparable between training
and test cohorts.
Features Train Test
T2w 0.89 (0.49-1.35) 0.93 (0.49 – 1.46)
T2w - Texture, G(1.5) 0.89 (0.56 – 1.24) 0.93 (0.59 – 1.34)
T2w - Texture, Gx(1.5) 0.00 (-0.11 – 0.10) 0.01 (-0.12 – 0.13)
T2w - Texture, Gy(1.5) 0.00 (-0.09 – 0.09) 0.00 (-0.09 – 0.11)
T2w - Texture, Gxx(1.5) 0.02 (-0.10 – 0.13) 0.01 (-0.14 – 0.14)
T2w - Texture, Gyy(1.5) 0.00 (-0.05 – 0.05) 0.00 (-0.06 – 0.06)
T2w - Texture, Gxy(1.5) 0.00 (-0.10 – 0.10) 0.00 (-0.11 – 0.14)
T2w - Texture, G(2.4) 0.90 (0.60 – 1.20) 0.95 (0.64 – 1.31)
T2w - Texture, Gx(2.4) -0.01 (-0.13 – 0.11) 0.01 (-0.14 – 0.15)
T2w - Texture, Gy(2.4) 0.01 (-0.10 – 0.11) 0.01 (-0.10 – 0.14)
T2w - Texture, Gxx(2.4) 0.03 (-0.10 – 0.15) 0.02 (-0.15 – 0.16)
T2w - Texture, Gyy(2.4) 0.00 (-0.06 – 0.06) 0.00 (-0.08 – 0.08)
T2w - Texture, Gxy(2.4) 0.01 (-0.10 – 0.14) 0.01 (-0.12 – 0.18)
T2w - Texture, G(3.8) 0.91 (0.65 – 1.19) 0.96 (0.70 – 1.30)
T2w - Texture, Gx(3.8) -0.01 (-0.15 – 0.12) 0.01 (-0.18 – 0.19)
T2w - Texture, Gy(3.8) 0.01 (-0.12 – 0.17) 0.02 (-0.12 – 0.19)
T2w - Texture, Gxx(3.8) 0.04 (-0.11 – 0.18) 0.01 (-0.16 – 0.17)
T2w - Texture, Gyy(3.8) 0.00 (-0.09 – 0.09) 0.00 (-0.10 – 0.11)
T2w - Texture, Gxy(3.8) 0.02 (-0.11 – 0.20) 0.02 (-0.13 – 0.23)
T2w - Texture, G(6.0) 0.93 (0.71 – 1.20) 0.99 (0.76 – 1.32)
T2w - Texture, Gx (6.0) -0.01 (-0.21 – 0.14) 0.01 (-0.21 – 0.22)
T2w - Texture, Gy (6.0) 0.03 (-0.16 – 0.21) 0.04 (-0.18 – 0.22)
T2w - Texture, Gxx (6.0) 0.04 (-0.15 – 0.19) -0.01 (-0.22 – 0.18)
T2w - Texture, Gyy (6.0) 0.00 (-0.12 – 0.11) 0.00 (-0.13 – 0.12)
T2w - Texture, Gxy (6.0) 0.04 (-0.17 – 0.25) 0.04 (-0.18 – 0.26)
ADC 1.1 (0.4 – 1.6) ×10−3 1.3 (0.6 – 2.5)×10−3
ADC blobness -0.2 (-0.4 – 0.2) ×10−3 0.2 (-0.4 – 0.3)×10−3
Ktrans 1.15 (0.48 – 2.70) 1.19 (0.54 – 2.83)
Ktrans blobness -0.17 (-0.88 – 0.42) -0.18 (-0.94 – 0.40)
kep 1.03 (0.52 – 1.83) 1.05 (0.44 – 2.62)
kep blobness 0.11 (-0.43 – 0.48) 0.14 (-0.47 – 798.32)
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Table S6.2: Feature ranking and coefficients. Gi(s) stands for the Gaussian derivative in the
direction i, with standard deviation s (in mm).
Rank Feature name β Rank Feature name β
1 kep - Intensity 2.7 17 T2w – Texture, Gxy (2.4) -134.0
2 kep - Blobness -0.9 18 T2w – Texture, Gyy (6.0) 1.5
3 Ktrans - Blobness -2.7 19 T2w – Texture, Gyy (3.8) -0.7
4 Ktrans - Intensity -1.5 20 T2w – Texture, Gxx (6.0) 1.6
5 ADC - Blobness 28206.0 21 T2w – Texture, Gx (6.0) -0.6
6 ADC - Intensity -965.0 22 T2w – Texture, Gyy (2.4) -7.2
7 T2w - Texture, G (3.8) 86.6 23 T2w – Texture, Gx (3.8) -1.2
8 T2w - Texture, G (6.0) 329.1 24 T2w – Texture, Gxx (3.8) -5.9
9 T2w - Texture, G (2.4) -281.9 25 T2w – Texture, Gy (1.5) 2.5
10 T2w - Texture, Gxx (1.5) -3.8 26 T2w – Texture, Gy (2.4) -118.6
11 T2w – Texture, Gxy (6.0) -70.9 27 T2w – Texture, Gy (3.8) -203.0
12 T2w – Texture, G (1.5) -133.7 28 T2w – Texture, Gyy (1.5) 5.5
13 T2w – Texture, Gy (6.0) -59.4 29 T2w – Texture, Gx (2.4) 5.0
14 T2w - Intensity -0.2 30 T2w – Texture, Gx (1.5) 1.9
15 T2w – Texture, Gxy(3.8) -183.3 31 T2w – Texture, Gxy (1.5) -18.4
16 T2w – Texture, Gxx (2.4) 5.1 Offset -3.75































































































































































































































































































































































































































































































































































































































































































































































































G E N E R A L D I S C U S S I O N
This thesis describes studies on the use of multi-parametric MRI for the detec-
tion and localisation of locally recurrent PCa after RT. We have found evidence
that pre-treatment T2w imaging features could potentially improve recurrence-
risk prediction models for high-risk PCa patients treated with RT. For the pur-
pose of RT treatment planning we have shown that, as an alternative to CT,
a combination of multiple MRI sequences can be used to detect fiducial mark-
ers automatically. Some patients will experience biochemical recurrence after
primary RT. Despite some studies describing the qualitative properties of multi-
parametric MRI after RT, no guidelines exist on how to evaluate and assess
recurrent PCa on mp-MRI. By characterising mp-MRI properties of irradiated
benign tissue and recurrent tumour, this thesis contributes towards a better
understanding of imaging in this challenging setting and can be used as a
foundation to establish guidelines on how to assess and score MRI scans. Im-
proving the general radiological knowledge in the radio-recurrent setting will
aid in the interpretation of images for the purpose of staging and patient se-
lection for salvage treatments. By providing evidence on how to define the
region to treat with local salvage strategies this thesis also contributes to the
refinement of localised salvage treatments.
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part 1: magnetic resonance imaging in the treatment
and outcome prediction of primary prostate cancer
Can pre-treatment MRI features be used to improve prediction of treatment
outcome?
Chapter 2 reports a study investigating the value of pre-treatment T2w MRI
features in predicting the risk of biochemical recurrence in high-risk PCa pa-
tients treated with EBRT. The standard clinical nomograms have limited ability
to distinguish different recurrence risk within a specific risk-group. Predicting
which men will develop biochemical recurrence could help identify patients who
would benefit from additional or more aggressive therapies but also targeted
follow-up for early detection of recurrent cancer. Multi-parametric MRI offers
the possibility to investigate prostate architecture and tumour heterogeneity
non-invasively and with this, devise imaging biomarkers. These biomarkers can
potentially describe some of the variability not explained by typically acquired
clinical parameters and allow for individualised patient risk-stratification. The
field of radiomics investigates the macroscopic heterogeneity of quantitative fea-
tures computed from medical images with the goal to probe the characteristics
of the underlying tissue [164]. In this study, we have found that combining high-
dimensional whole-prostate radiomic features, extracted from pre-treatment T2w
MRI scans, with a logistic regression classifier outperformed a model based
solely on clinical variables (AUC = 0.63 versus 0.51). Considering that this
was a clinically homogeneous cohort, the poor performance of a clinically-based
model was expected. According to PI-RADS v2, T2w alone is insufficient for
tumour detection [42] and thus whole-prostate features were used. By doing so,
no assumptions were made about tumour location and all available information
was taken into account, resulting in a less time-consuming procedure by circum-
venting the need to delineate the tumour region. Our results support previous
findings describing an association between tumour adjacent stroma and prostate
micro-environment to relapse and disease progression [73, 74]. As recurrence
occurs mainly at the site of the primary largest and/or highest-grade index
lesion [55, 57, 165, 166], it is reasonable to assume that the most crucial in-
formation would lie within the pre-treatment visible tumour region. In this case,
the use of features from the whole prostatic area might dilute the information
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provided by tumour-derived features and could explain the higher performance
obtained in the study by Gnep et al. [21] when using solely tumour-derived
features. The addition of functional MR imaging could potentially improve the
model predictions by providing physiological information and by enabling bet-
ter tumour localisation. In fact, there is new evidence that bi-parametric MRI,
using T2w and ADC-derived features, results in improved outcome predictions
when compared to the use of a single modality [167]. In addition to mp-MRI,
18F Choline- or 68Ga PSMA-PET might provide additional insight into the risk
of biochemical recurrence. Further research is needed to ascertain which ima-
ging sequences, features and region of interest would be optimal. The results
presented in this study offer a proof of concept of the potential of pre-treatment
radiological information in the context of precision medicine. Similar models
could help discriminate for which patients treatment intensification would be
beneficial and to design tailored follow-up schemes, with more frequent visits
for patients with higher risk of recurrence (Figure 7.1, Pre-treatment imaging).
Is it possible to automatically detect gold fiducial markers on MRI?
Fiducial markers (FM) are implanted in the prostate with the purpose of daily
position verification during the course of EBRT treatments. Moving towards
an MR-only environment will mitigate systematic spatial uncertainties present
when registering computed tomography (CT) and MRI [168]. However, a re-
quisite for the implementation of an MR-only workflow in RT is the ability
to identify the gold FM on MRI. In Chapter 3 we describe how our standard
mp-MRI sequences (T1-weighted, T2-weighted and a B0 map) acquired for the
purpose of treatment planning can be combined with dedicated sequences (bal-
anced steady-state free precession – bTFE, susceptibility weighted imaging –
SWI) to derive the FM position. Using CT-derived marker coordinates as the
ground-truth, we found that the combination of different sequences resulted in a
better performance than the best single imaging sequence (bTFE). By combin-
ing mp-MRI with bTFE the highest accuracy was obtained, with a true positive
rate of 0.94. Similarly, a study evaluating manual MR-based FM detection
found that multiple sequences led to better localisation performance compared
with the use of a single sequence [169].
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Accurate and reproducible manual FM localisation using MRI can be challen-
ging. The procedure is time consuming, affected by pixel-size and noise as
well as the quality of the software used for detection [106]. In addition, marker
appearance on imaging is impacted by sequence parameters and marker ori-
entation with respect to the magnetic field. The use of automatic detection
algorithms aims at facilitating MR-based FM localisation. A recent study com-
paring automatic with manual MR-based FM detection found that the spatial
accuracy and precision were comparable for both methods [170]. An automated
FM detection model could then be implemented to identify and superimpose
the FM in the derived pseudo-CT (Figure 7.1, Treatment planning). Brachy-
therapy seeds and FM will be present on the images acquired for the detection
of recurrent disease in EBRT and LDR-brachytherapy treated patients. Thus,
similar automated detection algorithms could be of use to identify them in this
setting (Figure 7.1, Diagnosis of recurrent PCa).
This is only one of the alternatives proposed to address this issue. Other op-
tions, mostly confined to the research setting currently, are the use of markers
that provide positive contrast on the MR images [171] and MR sequences adap-
ted to localise paramagnetic objects with high positive contrast [94]. Instead of
gold FM, the use of electromagnetic beacons that allow for real-time prostate
localisation has also been proposed [172]. The implementation of an MR-only
workflow mitigates the errors arising from multimodality registration. Currently,
automatic FM detection methods cannot yet fully eliminate manual interac-
tion but they can be used for an initial automatic localisation with possible
manual intervention in more complicated cases. The clinical implementation of
MR-Linac systems will allow for real-time MR-guided RT and will ultimately
eliminate the need to use FM.
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Figure 7.1: Schematic representation of a patient treatment chain and potential applications
of the findings from each of the chapters at the different time points.
part 2: magnetic resonance imaging for the detec-
tion and localisation of recurrent prostate cancer
Focal salvage treatments can be devised to overcome the toxicity associated
with whole-gland approaches. Having an accurate detection and a clear defin-
ition of local or distant disease at the time of biochemical failure is a crucial
aspect for patient selection, as the therapeutic ratio (treatment efficacy versus
treatment-related toxicity) is narrow in the recurrent setting. Multi-parametric
MRI is a non-invasive imaging tool that can be used to localise recurrent PCa.
However, MRI information is often underutilised as guidelines are lacking on
image interpretation in this setting. In the second part of this thesis we char-
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acterised and assessed mp-MRI for detection and localisation of recurrent PCa
after RT.
Radiation effects versus recurrent disease
What are the quantitative mp-MRI characteristics of benign tissue after ra-
diotherapy?
What are the quantitative mp-MRI characteristics of recurrent tumours after
radiotherapy?
These two questions have been addressed in Chapter 4 and 5, respectively.
A case-control set-up was used to describe and compare the imaging character-
istics of irradiated benign prostate tissue and radio-recurrent disease (Chapter
4). Imaging maps for benign central-gland and peripheral-zone were found to
be similar in both recurrent and non-recurrent patients. The peri-urethral tissue
had heightened enhancement in the Ktrans and kep maps without apparent signs
of malignancy for both recurrent and non-recurrent patients. This enhancement
could be considered a confounder for tumour detection in the central-gland.
While Ktrans values for recurrent tumour and peri-urethral tissue were not sig-
nificantly different, kep values were. This suggests that kep maps can be used
to discriminate benign enhancement from recurrent tumour in the central-gland.
While all imaging maps distinguished recurrent tumour from benign peripheral-
zone, the distinction between tumour and benign tissue in the central-gland was
only possible with ADC, Ktrans and kep. While T2w is the dominant sequence
in PI-RADS v2 for the detection of primary PCa in the transition zone, its
use is limited in the recurrent setting. Using mixed modelling we found that
a combination of the quantitative maps T2, ADC, Ktrans and kep together with
voxel location resulted in optimal distinction between tumour and benign voxels.
When comparing the imaging characteristics of patients with primary PCa be-
fore RT and those with recurrent disease after RT, we observed that the T2,
Ktrans and kep values for both peripheral-zone and central-gland were signi-
ficantly lower after the treatment (with the exception of the ADC values in
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the peripheral-zone). Nonetheless, no significant differences were seen for all
imaging values between recurrent and primary tumours.
While in Chapter 4 recurrent disease was defined on imaging and proved with
targeted biopsies, in Chapter 5 we aimed to characterise recurrent disease
more accurately. To do so, whole-mount histopathology slices of tissue from
patients treated with salvage prostatectomy for recurrent PCa after initial RT
were registered to MRI. Tumour delineations performed on pathology could in
this way be transferred to the MRI grid. We have found radio-recurrent dis-
ease to be often multifocal and with a different recurrence pattern in EBRT
and LDR-brachytherapy-treated patients. While recurrent disease after EBRT
consisted of large tumour foci, these were mainly small and sparse after LDR-
brachytherapy. In addition, recurrent PCa after LDR-brachytherapy was chal-
lenging to image due to the presence of the seeds, which caused severe distor-
tions in the DWI sequence potentially affecting the reliability of ADC values.
The clinical relevance and implications of tumour multifocality for the design
of focal salvage treatments are yet to be addressed. The contrasting patterns
of recurrence in EBRT and LDR-brachytherapy treated patients suggests that
different treatment strategies might need to be devised for each group.
The study presented in Chapter 5 further compared histopathology derived
delineations with those made manually by two radiologists, and found that
delineations based on mp-MRI tend to miss smaller foci and slightly underes-
timate the tumour volume of local recurrent PCa. A mixed modelling analysis
performed best in distinguishing tumour from benign tissue by using a combin-
ation of all imaging maps together with location information. The addition of
DCE parameters improved tumour distinction. The location significantly contrib-
uted to tumour likelihood because it acts as a surrogate to tumour prevalence,
which is typically higher in the peripheral-zone.
The results from these two studies suggest that DCE-MRI has an important
role in diagnosing locally recurrent disease. We did not find benign prostatic
hyperplasia (BPH) in the analysed pathology (Chapter 5), suggesting that
BPH vanishes after RT and is no longer a benign central-gland confounder.
However, increased enhancement of Ktrans and kep in the peri-urethral region
without signs of malignancy is present and needs to be considered when design-
ing guidelines. The value of T2w imaging is diminished in the detection and
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localisation of intraprostatic recurrent disease, and we suggest that its main role
should be confined to identifying extracapsular extension and seminal vesicle
invasion. The DWI sequence is limited by the presence of brachytherapy seeds
as these create severe susceptibility artefacts. A study exclusively investigating
recurrence after LDR-brachytherapy treatment found that DCE-MRI seems to
be superior to T2w and DWI in detecting recurrent disease [18]. The implement-
ation of a DWI sequence with an alternative sampling scheme [173, 174] (other
than echo-planar imaging) has been proposed to deal with this limitation. The
information presented in these studies can be used to devise guidelines to in-
terpret mp-MRI in the setting of recurrent PCa after RT (Figure 7.1, Diagnosis
of recurrent PCa).
Defining the volume to target with focal salvage treatments
Can mp-MRI be used to automatically define a region to treat with focal sal-
vage treatments?
In order to provide focal salvage treatments of recurrent PCa a delineation of
the target volume is necessary. MRI is commonly used for this task but, as
discussed in the previous chapters, no guidelines exist on how to assess and
delineate recurrent PCa on mp-MRI. In addition, in Chapter 5 we observed that
mp-MRI derived contours of recurrent tumour tend to underestimate the true
tumour volume. Following these findings, in Chapter 6 we propose a model
to derive regions to treat with focal salvage RT. A logistic regression model,
also referred to as tumour probability (TP) model, was trained on mp-MRI ima-
ging features. When tested on an independent cohort, the TP model obtained
a good diagnostic accuracy (AUC = 0.77). To deal with intrinsic image con-
founders and the uncertainties in defining a binary delineation we proposed the
use of a TP model with three levels of risk stratification (CTV, high-risk CTV
and GTV). In order to define these regions, the voxel-wise tumour probability
maps were further clustered on increasing probability of tumour presence. This
approach treats not only the GTV but it aims at mapping voxel-wise tumour
probabilities to proportionally increasing doses, and with this aims at compens-
ating possible tumour volume underestimation and covering microscopic spread.
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Model-derived tumour risk-levels achieved similar sensitivity and specificity as
manual delineations in localising the recurrent tumour.
Our previous studies have led to the conclusion that DCE-MRI is important
for the detection of recurrent disease after RT. In fact, in Chapter 6 the phar-
macokinetic maps kep and Ktrans seem to be the imaging parameters with the
greatest relevance in defining a voxel’s tumour risk. Finally, our results sug-
gest that to optimise tumour coverage, margins should be included around the
visible tumour. In this study, the high-risk clinical target volume surrounding
the gross tumour volume was patient specific and defined based on the mp-MRI
characteristics. In primary PCa, Hollmann et al. [175] reported the tumours
to be predominantly multifocal, and found that a fixed CTV margin would not
effectively cover all satellite tumours. We have also observed recurrent PCa
to be predominantly multifocal (Chapter 5). However, the clinical relevance
of tumour satellites is as yet unknown. If these can be considered indolent,
then focal salvage treatments covering only the index tumour lesion might be
sufficient. But it is also possible that these need to be treated to ensure local
control. In that case, and following Hollmann’s reasoning, it might be hard
to identify a fixed margin for the treatment of recurrent PCa. If considering
re-irradiation, a dose de-escalation regimen from the index tumour lesion could
be a suitable compromise between tumour coverage and normal tissue toxicity.
The overall findings demonstrate that it is possible to use mp-MRI information
to automatically derive volumes to target that could be used as a starting point
for treatment planning (Figure 7.1, Focal salvage treatment) for focal salvage
approaches in radio-recurrent PCa. Additional research should be performed to
validate the devised image-based models and to test the feasibility of including
such approaches within the patient treatment workflow.
part 2: mri for the detection and localisation of recurrent pca 139
implications for clinical practice
Currently, patients with high-risk characteristics are typically given more ag-
gressive treatment regimens, but their oncologic outcome is still heterogeneous.
Incorporating pre-treatment high-dimensional imaging-features can potentially
improve patient stratification. In addition, accurate delivery of RT treatment is
crucial in ensuring local tumour control while minimising normal tissue toxicity.
The implementation of an MR-only treatment planning workflow would not only
be logistically beneficial but it would also eliminate inter-modality registration
errors. A commercial MR-only simulation for RT planning is currently being
tested for the treatment of primary PCa at the Netherlands Cancer Institute.
A proportion of patients treated with RT will experience recurrent disease, and
those with locally recurrent tumours are candidates for focal salvage treatments.
Despite the fact that MRI is commonly used to diagnose and evaluate disease
extent, there are presently no guidelines on how to assess disease recurrence
from mp-MRI after RT. In this thesis, DCE-MRI was found to be very import-
ant in detecting and localising recurrent PCa. The data collected over the
course of these studies could ultimately be used in teaching sessions, and as
a foundation for establishing mp-MRI interpretation guidelines in the setting
of radio-recurrent PCa. Moreover, the different patterns of recurrent disease
after EBRT and LDR-brachytherapy treatments suggest that different salvage
strategies might need to be devised for the two groups. The design, and poten-
tially the effectiveness, of focal treatments are highly dependent on accurate
tumour localisation.
In this thesis we propose a model that uses mp-MRI information to derive target
volumes that could be used to initialise treatment planning. Focal salvage
interventions described in literature are typically MR-guided [54, 142, 176,
177], and could therefore benefit from the methodology presented here. Besides
mp-MRI, metrics from Choline and PSMA-PET should also be incorporated into
the design of focal salvage treatments.
In this thesis we provide data that enables a better understanding of mp-MRI in
the context of recurrent PCa after RT. This body of work provides an overview
of mp-MRI and its relationship with histopathology, which will be useful to
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establish radiological guidelines and help define better clinical practices in
the detection and localisation of radio-recurrent PCa. These can be used to
optimise the design of focal salvage treatments.
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S U M M A R Y

multi-parametric mri to guide salvage treat-
ment of recurrent prostate cancer
Depending on the tumour characteristics, up to 50% of patients treated
with radiotherapy for primary prostate cancer will experience recurrent disease
within 10 years of the primary treatment.
Chapter 2 shows evidence that pre-treatment T2w MRI features could po-
tentially improve the biochemical recurrence risk prediction in a clinically homo-
geneous patient cohort. The use of whole-prostate imaging features resulted in
an AUC = 0.63, outperforming a model solely based on clinical variables (AUC
= 0.51). With the goal of removing inter-modality registration errors and im-
proving the logistics of radiotherapy treatments, a new MR-only radiotherapy
treatment planning workflow is currently under investigation. Despite being
clearly visible on CT, the fiducial markers used for daily position verification
can be hard to detect on MRI. In Chapter 3 of this thesis we described how
features from T1w, T2w, B0 and a balanced TFE sequence can be combined to
automatically detect fiducial markers with a good accuracy and a true positive
detection rate of 0.94.
No clinical consensus exists on how to treat locally recurrent prostate can-
cer. Up to now, due to difficulties in assessing localised recurrent disease,
salvage treatment modalities were typically targeted at the entire gland. How-
ever, whole-gland salvage treatments resulted in high failure rates and severe
toxicity. Due to its high spatial resolution and functional possibilities, multi-
parametric MRI (mp-MRI) (comprising T2-weighted, diffusion-weighted imaging
(DWI) and dynamic contrast enhanced (DCE) MRI together with their derived
maps) has, in recent years, become the modality of choice to detect and isolate
locally recurrent cancer. Improved tumour visualisation and localisation has
fuelled the development of focal salvage treatment approaches, which aim at
targeting the tumour area while sparing the surrounding uncompromised tissue.
Nevertheless, information is lacking on the characteristics of prostate tissue
after radiotherapy on mp-MRI, and no guidelines or consensus exists on how to
detect and localise the region to target with focal salvage treatments. The main
purpose of the last three studies presented in this thesis was to improve the de-
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tection and localisation of recurrent prostate cancer after primary radiotherapy
treatment.
Chapter 4 uses mp-MRI to characterise benign irradiated tissue and recur-
rent prostate cancer. Imaging values for benign irradiated tissue were com-
parable between patients with and without recurrent prostate cancer, both
presenting with increased peri-urethral enhancement in the pharmacokinetic
Ktrans and kep maps without evident signs of malignancy. Benign central-gland
values were for all maps significantly decreased after radiotherapy, as well as
T2, Ktrans, and kep values of benign peripheral zone. Distinguishing recurrent
tumour from benign central-gland was not possible with T2 map. For all maps,
recurrent and primary prostate cancer tumours had similar imaging character-
istics.
In Chapter 5, the use of high-resolution histopathology delineations has
enabled an accurate study of recurrent tumour characteristics and a comparison
between manually-defined tumour regions and the ground-truth pathological
extent on mp-MRI. A different recurrence pattern was observed in external-
beam radiotherapy and low-dose brachytherapy treated patients. Delineations
based on mp-MRI tended to underestimate the real tumour extent and size,
suggesting that focal salvage strategies should include appropriate margins
around the visible tumour. In both studies (Chapter 4 and 5 ) the use of all
mp-MRI sequences (T2w / T2 map, ADC, Ktrans and kep maps) together with
the voxel anatomical location (peripheral zone or central gland), resulted in an
optimal distinction between tumour and benign voxels.
Chapter 6 uses mp-MRI information to create a tumour probability model
from which voxel-wise tumour probabilities can be obtained. The model’s highest
ranking features were derived from the DCE pharmacokinetic maps. Clustering
of the voxel-wise tumour probabilities was used to define a clinical target volume
(CTV), a high-risk CTV and a gross tumour volume (GTV). The sensitivity and
specificity of the high-risk CTV and GTV model-derived contours in localising
recurrent tumour were similar to those of manual tumour delineations based on
mp-MRI. This suggests that voxel-wise probabilities could in this way be incor-
porated for target definition in focal salvage treatments of recurrent prostate
cancer after radiotherapy.
164 summary
Chapters 4, 5 and 6 of this thesis highlight the importance of DCE-MRI
derived parameters for the detection and localisation of recurrent prostate can-
cer after radiotherapy. The findings presented in this thesis can be used as
a foundation to establish guidelines for tumour detection and definition of the
region to target with focal salvage treatments.
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S A M E N VAT T I N G

multi-parametrische mri voor de salvage be-
handeling van recidief prostaatkanker
Afhankelijk van de tumorkarakteristieken, zal tot 50% van de patiënten
behandeld met radiotherapie voor primaire prostaatkanker binnen 10 jaar na
de behandeling een recidief ontwikkelen. In Hoofdstuk 2 tonen we in een
klinisch homogene groep patiënten aan dat kenmerken in T2-gewogen MRI
beelden, gemaakt vóór de behandeling, een betere voorspelling mogelijk maken
van het risico op een biochemisch recidief. Het gebruik van karakteristieken in
de beeldvorming van de gehele prostaat, resulteerde in een AUC = 0.63, wat
een verbetering is ten op zichte van een model dat uitsluitend gebaseerd is op
klinische variabelen (AUC = 0.51).
Om registratiefouten tussen MRI en CT te vermijden en de logistiek van
radiotherapiebehandelingen te verbeteren, wordt momenteel een nieuwe werk-
wijze onderzocht voor een behandeling met radiotherapie, die voor beeldvorming
alleen gebaseerd is op MRI. Gouden markers, geïmplanteerd in de prostaat, zijn
op CT beelden goed zichtbaar en worden routinematig gebruikt voor dagelijkse
positieverificatie. Echter, op MRI beelden zijn deze markers moeilijk te de-
tecteren. In Hoofdstuk 3 van dit proefschrift hebben we beschreven hoe met
een combinatie van T1w, T2w, B0 en balanced-TFE-sequenties deze markers
automatisch kunnen worden gedetecteerd.
Tot op heden bestaat er geen klinische consensus over de behandeling van
een lokaal recidief van prostaatkanker. Tot nog toe waren behandelingen hier-
van doorgaans gericht op de gehele prostaat. Dit resulteerde echter in veel
bijwerkingen. Met een hoge spatiële resolutie en variatie in contrast, is multi-
parametrische MRI (mp-MRI), bestaande uit T2-gewogen, diffusie-gewogen
(DWI) en contrast-versterkte (DCE) MRI, de aangewezen manier om een lo-
kaal recidief van prostaatkanker te detecteren en af te lijnen. Dit biedt de
mogelijkheid om focale behandelingen uit te voeren, die zich enkel richten op
de recidief tumor, waarbij omliggend weefsel wordt gespaard. Echter, kennis
over de beeldvorming met mp-MRI van de bestraalde prostaat is beperkt. Richt-
lijnen ontbreken over hoe de beelden moeten worden geïnterpreteerd en hoe
de tumor moet worden afgelijnd. De laatste drie studies van dit proefschrift
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zijn daarom gericht op het verbeteren van de detectie en aflijning van recidief
prostaatkanker na eerdere behandeling met radiotherapie.
Hoofdstuk 4 beschrijft het gebruik van mp-MRI om de effecten van bestra-
ling op prostaatweefsel te karakteriseren. Kwantitatieve parameters, afgeleid
van mp-MRI waren bij patiënten zonder recidief vergelijkbaar met de waarden
die bij patiënten met recidief werden gevonden in de delen van de prostaat
waarin geen tumor voorkwam. In beide groepen was een verhoging te zien
rondom de urethra van de farmacokinetische parameters Ktrans en kep zonder
duidelijke tekenen van maligniteit. Ten opzichte van onbehandelde patiënten
waren in de rest van de prostaat T2, Ktrans en kep verlaagd. Dat verklaart
waarom het moeilijk is een recidief tumor te onderscheiden van omliggend weef-
sel. De recidief tumoren hadden vergelijkbare karakteristieken op mp-MRI als
onbehandelde tumoren.
In Hoofdstuk 5 hebben we beschreven hoe karakteristieken op mp-MRI
beelden samenhangen met histopathologie. Met gedetailleerde intekeningen
van recidief prostaat tumoren op de histopathologische coupes werden de in-
tekeningen van een radioloog op mp-MRI beelden gevalideerd. Bij patiënten
die behandeld waren met uitwendige radiotherapie, werd een andere verdeling
van recidief prostaatkanker waargenomen dan bij patienten behandeld met lage
dosis brachytherapie. Intekeningen op mp-MRI bleken de omvang van de tumor
te onderschatten, zoals waargenomen in histopathologie. Dit betekent dat bij
een focale behandeling een veilige marge rondom de zichtbare tumor in acht
moet worden genomen. In de studies beschreven in Hoofdstuk 4 en 5 bleek dat
met een combinatie van alle mp-MRI sequenties (T2w / T2 map, ADC, Ktrans
en kep mappen) het beste onderscheid gemaakt kon worden tussen tumor- en
goedaardige voxels.
Hoofdstuk 6 werd op basis van mp-MRI een model gemaakt waarbij op
voxelniveau de kans op aanwezigheid van tumor wordt weergegeven. De be-
langrijkste MRI karakteristieken voor het model waren gebaseerd op de far-
macokinetische parameters kep en Ktrans die zijn afgeleid van DCE-MRI. Op
basis van de kans op tumor werd een klinisch doelvolume (CTV) gedefinieerd
waarin zich microscopische tumor kan bevinden, een volume waarvoor een ern-
stige verdenking bestaat van aanwezigheid van tumor (high-risk CTV) en een
macroscopisch tumorvolume (GTV). De sensitiviteit en specificiteit van het high-
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risk CTV en GTV zoals afgeleid van het model, waren vergelijkbaar met die van
handmatige intekeningen. Dit betekent dat een model dat de kans op tumor op
voxelniveau weergeeft bruikbaar is voor het bepalen van een doelgebied voor
focale behandeling van recidief prostaatkanker na radiotherapie.
Hoofdstuk 4, 5 en 6 van dit proefschrift onderstrepen het belang van DCE-
MRI voor de detectie en lokalisatie van recidief prostaatkanker na radiotherapie.
De resultaten die in dit proefschrift zijn gepresenteerd, kunnen gebruikt worden
als basis voor het opstellen van richtlijnen voor detectie van recidief tumoren
in de prostaat en het aflijnen van het doelgebied voor een focale behandeling.
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S U M Á R I O

ressonância magnética multiparamétrica como
meio de guiar o tratamento do cancro da
próstata recorrente
O cancro da próstata é uma condição patológica que afecta mais de 40%
dos homens com idades acima de 60 anos. Um dos tratamentos mais comuns
para o cancro da próstata é a radioterapia. Contudo, mesmo depois do trata-
mento de radioterapia, existe a possibilidade de que o tumor volte a crescer
e, caso tal aconteça, falamos de uma recidiva ou um tumor recorrente. Vários
factores podem influenciar o risco de recidiva, como por exemplo a extensão ou
a agressividade do tumor inicial. O Capítulo 2 descreve os resultados obtidos
quando uma sequência anatómica (T2w) de ressonância magnética (RM) adqui-
rida antes do tratamento inicial de radioterapia é usada para prever o risco
que um paciente tem em sofrer uma recidiva. Parâmetros clinicos, tal como
a extensão do tumor ou o grau de diferenciamento, são usados como meio de
prever o risco de recorrência. O cancro da próstata pode ser assim categori-
zado em três grupos de risco (baixo, médio e alto), e a escolha do tratamento
é feita com base nestes parâmetros. Em concreto, este estudo focou-se num
grupo clinicamente homogéneo de pacientes com tumores de alto risco, em que
em alguns dos casos o paciente sofreu uma recidiva enquanto em outros não.
Neste estudo demonstramos que um classificador que utiliza as características
extraídas da imagem na região da próstata é capaz de superar um classificador
que usa apenas parametros clínicos no que toca a prever o risco de recidiva.
Havendo a possibilidade de ter acesso a priori à informação de que um paci-
ente tem um alto risco de recidiva, é possivel oferecer um regime de tratamento
intensificado ou um maior acompanhamento.
Durante o planeamento do tratamento de radioterapia, a RM é utilizada
para a delineação das estruturas enquanto que as doses são calculadas usando
a tomografia axial computarizada (TAC). Recentes avanços no planeamento do
tratamento de radioterapia focam-se na completa remoção do TAC, sendo então
as suas tarefas substituidas pela RM. Marcadores fiduciais são implantados no
paciente para o posicionamento diário durante as diferentes frações do trata-
mento. Apesar de visíveis no TAC, estes são dificeis de detectar na RM. No
Capítulo 3 demonstramos que uma combinação de várias sequências de RM
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podem ser utilizadas para automaticamente identificar os marcadores fiduciais
com uma boa precisão.
Para os pacientes com uma recidiva localisada sem a presença de metásta-
ses distantes, há uma última opção possível de tratamentos curativos, aos quais
se dá o nome de tratamentos de resgate. Existem vários tipos de tratamen-
tos de resgate, mas estes não são frequentemenete oferecidos pois as chances
de sucesso são limitadas e é comum resultarem em efeitos colaterais sérios e
persistentes. Com o objectivo de diminuir os efeitos tóxicos dos tratamentos
convencionais de resgate que tratam a próstata por completo, está a ser investi-
gada a possibilidade de tratar apenas o tumor. A perspectiva é de que ao tratar
apenas a zona onde se encontra o tumor, a toxicidade para os tecidos e orgãos
na periferia da próstata seja diminuida. Para poder oferecer esta opção de
tratamento é necessária uma identificação atempada de recorrência enquanto
esta ainda é localizada. Métodos de diagnóstico, tal como a ressonância mag-
nética multiparamétrica (mp-RM) que possibilita a obtenção de imagens não só
da anatomia mas também da fisiologia dos tecidos, oferecem uma oportunidade
para a detecção atempada do tumor recorrente. Este é também o método mais
comum de localizar o tumor que deve ser visado com os métodos focais de trata-
mento de resgate. Contudo, pouca informação existe sobre as características do
tecido da próstata depois do tratamento inicial com radioterapia. O objectivo
principal dos capítulos apresentados na segunda parte da tese é o de melhorar
a detecção e a localização do tumor recorrente após o tratamento inical com
radioterapia.
Para tal, o Capítulo 4 utiliza mp-RM para a caracterização tanto do tumor
recorrente como dos tecidos benignos. A estrutura do estudo foi caso-controle,
e portanto o grupo analisado era constituído tanto por pacientes com tumor
recorrente como por pacientes sem suspeita de recorrência. Foram ainda anali-
sadas imagens de pacientes antes de receberem o tratamento de radioterapia.
Como tal, foi assim possível fazer uma caracterização quantitativa de mudan-
ças benignas provavelmente induzidas pelo tratamento de radioterapia. Tanto
imagens anatómicas como funcionais foram analisadas nas diferentes regiões
da próstata e no tumor recorrente. A informação descrita neste estudo ajuda
na interpretação das images e para que o tumor consiga ser distinguido de
mudanças benignas originadas pela radioterapia.
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O Capítulo 5 foca-se no estudo do tumor recorrente, utilizando não só ima-
gens adquiridas aquando do diagnóstico da recorrência, mas também a amostras
patológicas obtidas quando estes pacientes foram sujeitos a uma cirúrgia de
remoção da próstata como tratamento de resgate. Foi assim possível utilizar
delineações de alta resolução, obtidas com base na patologia e transferidas
para as imagens de RM, para um estudo preciso das características do tumor
recorrente. Delineações foram também feitas por dois radiologistas experien-
tes com base na mp-RM. Quando estas últimas delineações foram comparadas
com as que foram obtidas através da patologia foi possivel observar que a ver-
dadeira extensão e tamanho do tumor tendem a ser subestimados, sugerindo
que estratégias focais de tratamento de resgate devem incluir margens à volta
do tumor visível na mp-RM. A combinação das imagens anatómicas T2w /T2
map e funcionais ADC, Ktrans and kep em conjunto com a localização dentro da
próstata resultou em ambos os estudos (Capítulos 4 e 5 ) na melhor distinção
entre tumor e tecido benigno.
Por fim, o Capítulo 6 demonstra como as sequências de mp-RM podem ser
usadas num modelo para criar um mapa que indica para toda a próstata qual
é a probabilidade de conter tumor. As imagens que mais contribuíram para
esta distinção foram o kep and Ktrans, derivadas com base nas propriedades
de perfusão dos tecidos. As probabilidades foram posteriormente aglomeradas
para criar 3 zonas com um risco incremental de conterem tumor. Estas regiões
foram comparadas com as delineações obtidas a partir da patologia. Foram
observadas sensibilidades relativamente baixas mas alta especificidade em de-
tectar o tumor recorrente. Ao comparar as regiões definidas pelo modelo com as
delineações feitas por dois radiologistas experientes foi possivel observar que
estas eram semelhantes em termos de sensitividade e especificidade. Estes re-
sultados sugerem que estes mapas de probabilidades podem ser incorporados
no planeamento de tratamentos focais de resgate.
Em conclusão, os resultados descritos nos capítulos desta tese podem ser
usados como base para estabelecer directrizes em como detectar e localizar a
região a tratar com os tratamentos focais de resgate. Os últimos três capítulos
realçam ainda a importância dos parâmetros de perfusão na identificação do
tumor recorrente. Por fim, modelos que utilizem a mp-RM podem ser úteis para
uma definição automática do tumor a tratar com opções focais de resgate.
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